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ABSTRACT 
Characterization of Human Hsp70 Chaperone Complexes and Chemical Control 
Over Their Formation 
 
by 
Srikanth Patury 
Chair: Jason E. Gestwicki 
 
Heat shock protein 70 (Hsp70) is a molecular chaperone that plays a central role in 
cellular protein homeostasis by assisting in the folding and/or degradation of protein 
substrates. In these tasks, Hsp70 is assisted by associated co-chaperones, each of which is 
thought to contribute to specialized chaperone functions. However, it isn’t yet clear why 
specific co-chaperones are recruited to the Hsp70 complex and how each distinct 
complex is able to carry out specific tasks. Further, imbalances in this system are thought 
to be involved in human diseases, such as cancer and neurodegenerative disorders. Thus, 
chemically controlling the formation/function of Hsp70-based chaperone complexes 
 xvi 
 
could provide new insights into the logic of protein quality control and also provide new 
avenues for drug discovery.  
The goals of this work are (a) biochemically characterize distinct Hsp70 complexes to 
permit insights into their specialized functions and (b) identify and characterize chemical 
compounds that promote the formation of specific Hsp70 complexes. Towards these 
goals, we devised a new approach termed “gray-box” screening, in which high 
throughput chemical screens are performed against reconstituted components of the 
Hsp70 chaperone family, facilitating the identification of compounds that target specific 
protein-protein interfaces in the Hsp70 complex. Using this approach, we found 
unexpected allosteric mechanisms for some of these compounds. For example, we found 
that 115-7c stimulates the ATPase and protein-folding activities of Hsp70 by promoting 
the action of the co-chaperone Hsp40. To further extend this screening method, we 
biochemically characterized ~12 distinct Hsp70 complexes formed from reconstitution of 
recombinant, human co-chaperones. These findings are expected to facilitate a large 
number of additional “gray box” screens. Finally, we extended this work to the Hsp70 
complex with CHIP, a co-chaperone that is emerging as a critical regulator of the pro-
degradation activities of Hsp70. Together, these studies have provided important new 
insights into the molecular mechanisms of Hsp70 chaperone system, including key 
differences between the prokaryotic and human chaperones. This work has also provided 
chemical probes that will be useful in understanding the roles of protein-protein 
interactions in the Hsp70 complexes. 
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Chapter 1 
 
Introduction to the Hsp70 Chaperone Complexes 
and Their Use As Potential Drug Targets 
 
1.1 Abstract 
The molecular chaperone, heat shock protein 70 (Hsp70), is involved at multiple steps in 
a protein’s life cycle, including during the processes of folding, trafficking, remodeling 
and degradation. To accomplish these various tasks, the activity of Hsp70 is shaped by a 
host of co-chaperones, which bind to the core chaperone and influence its functions. 
Genetic studies have strongly linked Hsp70 and its co-chaperones to numerous diseases, 
including cancer, neurodegeneration and microbial pathogenesis, yet the potential of this 
chaperone as a therapeutic target remains largely underexplored. Here, we review the 
current state of Hsp70 as a drug target, with a special emphasis on the important 
challenges and opportunities imposed by its co-chaperones, protein-protein interactions 
and allostery.  
 
 
 
  
2 
1.2 Structure and Function of Hsp70 Family 
 
1.2.1 Introduction  
Heat-shock protein 70 (Hsp70) is a molecular chaperone that interacts with exposed 
hydrophobic residues in nascent polypeptides and guides these substrates into one of 
several distinct fates [1-4]. This chaperone assists newly synthesized proteins during their 
entry into the folding pathway, but it also mediates trafficking, quality control and 
degradation [5-8]. In addition to its activities on nascent proteins, Hsp70 interacts with 
folded and partially folded substrates; for example, it is involved in nuclear hormone 
signaling, mediates the remodeling of multi-protein complexes and is required for 
clathrin re-organization during endocytosis [9-12]. Thus, Hsp70 is able to intersect with a 
protein during virtually every stage of its life cycle: from primary folding to function and 
degradation. Moreover, Hsp70 is thought to bind promiscuously to non-polar sequences, 
so it is able to serve as a core chaperone for the proteome [13, 14]. Because of this 
diversity and breadth of functions, Hsp70 is considered a central mediator of protein 
homeostasis.  
 
Hsp70 is abundant (~ 1-2% of total cellular protein) and highly conserved, with 
approximately 50% sequence identity between prokaryotic and mammalian family 
members. In addition, many organisms express multiple Hsp70s (e.g. 13 in humans) and 
members are found in all the major subcellular compartments. One of the functions of 
Hsp70 in these regions is to protect against cellular stress. Accordingly, its expression, 
like that of many other heat shock proteins, is controlled by the stress-responsive 
3 
transcription factor, heat shock factor 1 (HSF1). To add functionality to this system, the 
Hsp70s also interact with a variety of co-chaperones. These associated factors help 
Hsp70’s substrates find their fates and, together, this network regulates protein 
processing and makes the cell responsive to changes in the folding environment. 
However, the complexity of Hsp70’s functions also creates numerous challenges in 
designing safe and effective therapeutics that target this chaperone [15]. In this review, 
we will discuss Hsp70’s roles in disease and specifically focus on how structure and 
function studies might assist identification of therapeutic leads.  
 
1.2.2 Domain Architecture  
Hsp70 is a 70 kDa, dynamic molecular machine that hydrolyzes ATP and binds exposed 
hydrophobic peptides. 
These diverse tasks are 
accomplished by a 
relatively minimal 
structure composed of 
three major domains: a 
~44 kDa N-terminal 
nucleotide binding 
domain (NBD), a ~15 
kDa substrate binding 
domain (SBD) and a ~10 
kDa C-terminal alpha helical, “lid” domain (Figure 1.1). The NBD contains the important 
4 
site of ATP binding and hydrolysis, which is critical to Hsp70’s chaperone functions. 
When ATP is bound, the SBD and NBD exhibit coupled motion, suggestive of their tight 
association [16, 17]. Also in this ATP-bound form, the lid domain remains open, which 
facilitates transient interactions with substrates (Figure 1.2). Following ATP hydrolysis, a 
conformational change releases the SBD, resulting in closure of the lid and a ~10-fold 
increase in the affinity for substrate [18, 19]. The conformation change associated with 
ATP hydrolysis is communicated through a key proline switch and involves the 
conserved, hydrophobic linker that connects the NBD to the SBD [20]. Together, these 
structural and biochemical studies have begun to reveal the dynamic changes in Hsp70 
that accompany nucleotide hydrolysis and substrate binding [21]. However, the intrinsic 
ATPase rate of Hsp70 is remarkably slow (on the order of 0.2 nmol/µg/min) [22]. This 
situation allows for regulation by multiple factors, including substrates and associated co-
chaperones, which bind Hsp70 and modify nucleotide turnover. Because the ATPase 
activity of Hsp70 is central to controlling its structure and function, these regulatory 
interactions are likely key to understanding chaperone biology.  
 
1.2.3 J-domain co-chaperones 
The J-domain proteins are a large class of Hsp70-associated co-chaperones; there are six 
of these proteins in Escherichia coli, ~20 in Saccharomyces cerevisiae and ~40 in 
humans [23, 24]. These factors are characterized by a conserved ~70 amino acid J-
domain, which is named after the founding member of the class, E. coli DnaJ. The main 
role of this domain is to stimulate the intrinsically slow ATPase activity of Hsp70 [25, 
26] and the key region involved in this process is an invariant histidine-proline-aspartic  
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acid (HPD) motif, which resides in a loop between helix 2 and 3 of the J-domain [27-29].  
Interactions between the J-domain and Hp70’s NBD stimulate ATPase activity by 
approximately 5- to 10-fold [22, 30], resulting in enhanced substrate affinity.  
 
In addition to the J-domain at their N-termini, members of this co-chaperone family 
contain a wide variety of distinct domains at their C-termini. The identity of this C-
terminal domain is used for classification; briefly, proteins in class I and II contain 
domains involved in dimerization and substrate binding [31, 32], while the class III 
members have domains with a variety of predicted functions [33]. Consistent with this 
diversity of functions, deletion studies have suggested that individual J protein co-
6 
chaperones play distinct cellular roles. For example, complementation studies involving 
thirteen cytosolic J domain proteins revealed that at least four examples (Sis1, Jjj1, Jjj3, 
Cwc23) fulfill unique functions in yeast [34]. For Sis1, its C-terminal region was 
responsible for its specificity because fusing it to the J-domain of Ydj1 was sufficient to 
suppress the loss-of-function phenotype [35]. Similarly, the mammalian J-domain 
protein, DJA2, is competent for refolding of denatured proteins in vitro, but the related 
co-chaperone, DJA1, is not [36]. These and other studies have repeatedly shown non-
overlapping roles for the J-proteins [24, 37, 38]; however, how these factors assemble 
and exchange on Hsp70 in vivo remains unclear. 
 
1.2.4 Nucleotide exchange factors 
Completion of Hsp70’s ATPase cycle requires release of ADP, which is a process that is 
catalyzed by another class of co-chaperones, the nucleotide exchange factors (NEFs). 
These co-chaperones accelerate ADP release through interactions with the NBD and they 
can be categorized into four distinct, evolutionarily unrelated families named after 
representative members: GrpE, Bag1, Hsp110 and HspBP1. Prokaryotic GrpE was shown 
to increase the rate of release of nucleotide from the bacterial Hsp70, DnaK, without 
affecting the rate of hydrolysis [39]. Similar findings were shown with the mammalian 
counterparts [40]. Together with DnaJ, GrpE stimulates the overall ATPase activity of 
DnaK by ~50 fold [41], which suggests that the active, physiological chaperone is 
minimally composed of this multi-protein complex [42, 43]. Co-crystallization revealed 
that a dimer of GrpE binds asymmetrically to a single molecule of DnaK and forces the 
lobes of the NBD open by 14° [44]. In addition to its roles as a NEF, GrpE has also been 
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shown to function as a thermosensor; it reversibly unfolds in response to heat shock, thus 
decreasing the rate of nucleotide exchange and favoring substrate retention until 
conditions improve [43, 45, 46]. The second class of NEFs is named after Bag-1 (Bcl-2-
associated athanogene-1), which was the first eukaryotic exchange factor to be identified 
[47]. This family contains 6 members in humans, characterized by a C-terminal BAG 
domain that interacts with Hsp70. Like GrpE, the BAG domain induces a 14° outward 
rotation in the NBD [48, 49]. The conservation of this mechanism is interesting because 
BAG domains are structurally and evolutionarily unrelated to GrpE. Importantly, the 
BAG family members typically possess a variety of additional protein-protein interaction 
motifs and, like the J-domain co-chaperones, these regions are thought to bring unique 
capabilities into the Hsp70 machinery. For example, Bag1 has an ubiquitin-like domain 
through which it interacts with the proteasome, stimulating degradation of Hsp70 
substrates [50]. Although GrpE and Bag-1 share mechanistic features, the other major 
classes, HspBP1 and Hsp110, are both structurally and functionally distinct. For example, 
the co-crystal structure of HspBP1 revealed that this NEF reduces the affinity for 
nucleotide by displacing one lobe of the NBD [51]. Members of the Hsp110 family are 
structurally similar to Hsp70 and, consistent with this observation, they protect against 
aggregation of heat-denatured proteins in addition to their NEF functions [52-56]. 
Importantly, the substrate-binding activity of Hsp110 is strictly associated with ‘holdase’ 
outcomes and these factors are not competent in the refolding of denatured substrates. 
Together, these four classes of NEFs comprise a diverse array of important co-
chaperones that interact in only partially overlapping regions on the Hsp70 surface. 
Moreover, like J-domain proteins, they possess separate, intrinsic capabilities and/or 
8 
interact with other cellular pathways to recruit Hsp70 into a variety of tasks. 
 
1.2.5 TPR-domain proteins 
The tetratricopeptide repeat (TPR) is a 34 amino acid motif that binds to a region at the 
extreme C-terminus of Hsp70’s lid domain, which is characterized by four conserved 
amino acids, EEVD. Interestingly, the C-terminal EEVD motif is found in both Hsp70 
and Hsp90, but not the prokaryotic DnaK or the mitochondrial or ER-resident Hsp70 
isoforms. The structure of a representative TPR reveals that it interacts with the 
negatively charged side chains of the linear EEVD peptide [57]. In addition, residues 
upstream of the conserved EEVD are also recognized and these sites have been 
hypothesized to provide specificity [58, 59]. Binding of some TPR domains appears to be 
dependent on the nucleotide state of Hsp70, for example, the TPR-domain protein, Hop, 
binds tighter to the ADP-bound form [60]. Moreover, yeast Sti1 can actively stimulate 
the ATPase activity of the yeast Hsp70 Ssa1 [61], suggesting crosstalk between the TPR 
co-chaperones and nucleotide turnover [62]. In addition to their ability to bind Hsp70 and 
regulate ATP hydrolysis, the various TPR-containing proteins exhibit an array of 
additional activities, provided via their other domains. For example, Hop has two TPR 
domains and it mediates the association between Hsp70 and Hsp90 [63]. Hop-mediated 
substrate transfer between these major chaperone networks is thought to be critical to 
some functions, such as nuclear hormone receptor signaling [10, 64]. Conversely, CHIP 
(carboxyl terminus of Hsc70 interacting protein) is a TPR-domain protein that both 
inhibits J-domain-stimulated ATPase activity and also contains a U-box domain 
associated with E3 ubiquitin ligase activity. Through this modality, CHIP has been shown 
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to ubiquitinate Hsp70 substrates, diverting them to the proteasome [65-68]. Thus, CHIP 
functions as a chaperone-associated, quality control monitor that can tag substrates for 
degradation. Knockouts of CHIP are viable and show distinct phenotypes [69], 
suggesting that this co-chaperone plays roles that are not entirely redundant with other 
TPR family members.  
 
1.2.6 Hsp70 as a Combinatorially Assembled Machine 
Mammalian cells contain approximately 13 Hsp70s, over 40 J-domain proteins, at least 4 
distinct types of NEFs and (conservatively) dozens of proteins with TPR-domains. At any 
given time, an individual Hsp70 molecule can only interact with a single representative of 
each major class; therefore, in theory, tens of thousands of possible complexes might be 
formed (Figure 1.3). Thus, a major question in chaperone biology is how these various 
components are assembled and whether different combinations always lead to specific 
outcomes. The answer to this question might lead to a better understanding of how Hsp70 
can engage in its dizzying array of biological process, from folding to trafficking, 
endocytosis and protein turnover. Moreover, understanding the emergent properties of 
each complex might provide insight into how Hsp70 can act on such a wide range of 
substrates. Moreover, this ‘combinatorial assembly’ hypothesis creates a number of 
important challenges and opportunities for drug discovery. Although perturbation of 
protein-protein interactions has become increasingly common [70-72], the path to these 
compounds remains less straightforward. Given that Hsp70 is central to many cellular 
processes, effective and safe compounds might be required to act on specific Hsp70 
complexes in order to avoid toxicity associated with global disruption of proteostasis.  
10 
 
 
1.3 Roles of Hsp70 in Disease 
Consistent with Hsp70’s many roles in the maintenance of the proteome, genetic studies 
have implicated this chaperone in numerous diseases. In some of these instances, disease 
pathology is associated with “too much” Hsp70 activity (e.g. aberrant stabilization of a 
specific substrate). In other examples, defects appear to arise from a failure of Hsp70 to 
properly recognize and remove misfolded substrates. Thus, disease might arise from 
disruption of the proteostasis network in either direction. In this section, we will briefly 
outline some of the molecular roles for Hsp70 in disease and point out some of the 
11 
remarkably diverse opportunities for therapeutic intervention.  
 
1.3.1 Cancer 
Hsp72, a stress inducible Hsp70, is known to directly inhibit several steps in apoptotic 
signaling, including both intrinsic and extrinsic pathways [73]. Hsp72 inhibits lysosomal 
membrane permeabilization [74], activation and translocation of pro-apoptotic factors 
such as JNK, BID, BAX, or AIF, and release of cytochrome c from mitochondria. In 
addition, Hsp72 has been shown to suppress cellular senescence pathways [75, 76]. 
Consequently, its levels are elevated in several cancer cell lines and overexpression of 
this chaperone is correlated with poor prognosis [77] and resistance to chemotherapies 
[78]. Important roles have also been attributed to the mitochondrial Hsp70 isoform, 
mtHsp70 or Grp75, which was identified as a mortality factor in cancer and thus named 
"mortalin". mtHsp is over-expressed in breast, colon and colorectal cancer cells and its 
upregulation has been shown to induce malignant transformation in a mouse model [79, 
80]. Moreover, RNAi knockdown of the chaperone causes growth arrest in human 
immortalized cells [81]. Finally, the ER-localized BiP has also been implicated in cancer 
[82]. It is highly expressed in glioblastomas and its expression exhibited a negative 
relationship with patient survival [83]. Recently, BiP was found to promote angiogenesis 
and assist proliferation of tumor cells [84]. Together, these studies illustrate Hsp70’s anti-
apoptotic roles, consistent with a general capacity as a stress-inducible, pro-survival 
factor. 
 
Based on these studies, Hsp70 has been proposed to be a potential drug target in cancer. 
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In part, this model is based on parallel studies on Hsp90. Briefly, Hsp90 is thought to 
both enhance the cellular capacity to accommodate otherwise toxic proteins, while also 
preventing the onset of apoptosis by stabilizing pro-survival substrates, such as Akt [85-
90]. Inhibitors of Hsp90 show selective toxicity against cancer cells in vitro and they are 
currently in multiple clinical trials [91]. Interestingly, Hsp90 in tumor cells is 
predominantly complexed with its co-chaperones, whereas, normal cells contain higher 
levels of free (or latent) Hsp90 [92]. Consistent with this concept, the Hsp90 inhibitor, 
17-AAG, binds with higher affinity to the Hsp90 complex than to the latent chaperone, 
suggesting a mechanism for specific toxicity in cancer cells. The analogous studies have 
not been thoroughly performed for Hsp70, but, as discussed above, this chaperone is also 
known to interact with numerous substrates and co-chaperones. Moreover, Hsp90 and 
Hsp70 appear to share common substrates in anti-apoptotic signaling and both 
chaperones are over-expressed in tumor cells, presumably because of the higher demand 
for protein folding and the stressful microenvironments that these cells encounter. Thus, 
Hsp70 may also be a good target for anti-cancer strategies in much the same way as 
Hsp90. 
 
One interesting aspect of Hsp90-based treatments, which has yet to be thoroughly 
explored for Hsp70, is the ability of some Hsp90 inhibitors to induce a compensatory 
stress response. Hsp90 inhibitors lead to over-expression of Hsp72 and many other heat 
shock proteins, through release of HSF1[93, 94]. Briefly, the transcription factor, HSF1, 
is held in an inactive state by the Hsp90 complex. Accumulation of misfolded substrates 
diverts the chaperone, triggers nuclear localization of HSF1 and upregulates targets 
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involved in protection from cellular stress. This feedback loop has been hypothesized to 
decrease the overall effectiveness of Hsp90 inhibition by enhancing the overall chaperone 
pool[95, 96]. Moreover, these observations suggest that the efficacy of Hsp90 inhibitors 
may be improved by co-administration with Hsp70 inhibitors. Consistent with this idea, 
Guo et al. used siRNA against Hsp70 to increase the efficacy of 17-AAG in cancer cells 
[97]. Recently, Powers et al. showed that simultaneous suppression of two cytosolic 
Hsp70s, Hsc70 and Hsp72, also sensitized cancer cells to 17-AAG [98]. Together, these 
findings highlight the inter-connectivity of the chaperone networks and the ability of the 
basic biological knowledge to assist in design of therapeutic strategies. 
 
1.3.2 Neurodegenerative and Protein Misfolding Diseases 
Many neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases, are 
characterized by abnormal protein misfolding and accumulation [99-101]. In these 
disorders, misfolded proteins are not properly cleared by the chaperone / quality control 
system and they self-associate into cytotoxic oligomers. Conversely, indications such as 
cystic fibrosis and Gaucher disease involve premature protein degradation [102]. For 
example, certain point mutations in the cystic fibrosis transmembrane receptor (CFTR) 
cause misfolding and premature degradation in the secretory pathway, leading to 
pathology consistent with CFTR loss-of-function. Thus, many important and challenging 
diseases involve alterations in protein homeostasis, but some diseases might involve “too 
little” chaperone function while others appear to arise from “too much” of this activity. 
Recently, the “proteostasis boundary” hypothesis has been put forward to describe the 
concept of cellular protein folding capacity and its relationship with disease [103]. 
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Briefly, the folding capacity of the cell (e.g. the chaperone network, the proteasome and 
related quality control systems) is normally able to catalyze the folding or timely 
degradation of proteins within the proteome. However, aging, mutation or environmental 
stress can disrupt this balance and place individual substrates beyond the boundary of the 
cellular capacity. According to this model, accumulation of misfolded proteins during 
neurodegeneration might overwhelm the network and lead to widespread failures. 
Alternatively, boundaries that are too restrictive might trigger loss-of-function 
phenotypes via premature clearance. Because of its central and diverse roles in protein 
processing, it isn’t surprising that Hsp70 has been linked to both types of disorders [104, 
105]. For example, Hsp70 has been over-expressed in S. cerevisiae [106], mouse [107, 
108], Caenorhabditis elegans [109] and Drosophila melanogaster [110-112] models of 
neurodegenerative disease. In each of these experiments, high levels of Hsp70 were 
found to partially restore normal physiology. Similarly, pharmacological induction of 
Hsp70 has been found to mirror the beneficial effects of chaperone over-expression in 
some models. Compounds such as 17-AAG or celasterol, which stimulate a stress 
response and enhance expression of heat shock proteins, are sometimes protective in 
protein misfolding disease [113, 114]. This recovery is thought to result, in part, from 
enhanced capacity to process proteins, combined with enhanced pro-survival signaling. 
Conversely, reduction of chaperone function has been found to be beneficial in cases 
involving premature protein degradation; or example, mutation of either Hsp70 or the J-
domain co-chaperones, ydj1 and hlj1, reduces aberrant degradation of CFTR in models of 
cystic fibrosis [115, 116]. Thus, the relationship between Hsp70 and disease is complex, 
and the desired properties of a therapeutic are expected to be dependent on the specific 
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damage to the proteostasis boundary. 
 
Consistent with this idea, Hsp70’s regulatory co-chaperones are also thought to be 
important in disease. For example, the interaction of Hsp70 with the TPR-domain 
proteins CHIP[117-119] and BAG2[120] are important for clearance of tau, a protein 
implicated in Alzheimer’s disease and frontotemporal dementia. Over-expression of the 
J-domain co-chaperone, Hsp40 (E6-AP), has been found to be sufficient to inhibit 
polyglutamine aggregation[106, 121]. Similarly, RNA interference of the Hsp90 co-
chaperone, Aha1, also partially recovers CFTR stability [122]. These genetic findings 
suggest that both Hsp70 and its co-chaperones belong to a defense system that normally 
counteracts neurodegenerative disease. Together, these findings point to the Hsp70 
complex (e.g. the core chaperone and its associated factors) as potential targets for 
pharmacologic intervention in neurodegenerative and protein misfolding disorders. 
 
1.3.3 Microbial Pathogenesis 
The prokaryotic Hsp70, DnaK, has been strongly linked to bacterial survival under stress 
[123-126]. In addition, Hsp70s have also been linked to malarial infection [127] and host-
pathogen interactions [128]. Consistent with these roles, knockouts of E. coli DnaK are 
viable under normal laboratory conditions, but they are sensitive to elevated temperature 
[129] or addition of antibiotics [125]. Moreover, null mutations in DnaK make 
Staphalococcus aureus less efficient in mouse infection models [126] and Streptococcus 
mutans dnakΔ strains have impaired biofilm formation [124]. Consistent with the idea 
that the entire Hsp70 chaperone system is important in disease, knockouts of the 
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regulatory co-chaperone, DnaJ, also show growth defects under stress conditions [125, 
130]. Together, these observations have led to the hypothesis that inhibitors of DnaK and 
its co-chaperones might have antibiotic applications. Importantly, the expected 
mechanism would be to sensitize pathogens towards additional stresses. 
 
1.3.4 Other Diseases 
In addition to being implicated in cancer, protein misfolding disorders and infection, 
Hsp70 and its co-chaperones have been associated with numerous other diseases, 
including Crohn’s disease [131] and ALS [132], and this chaperone plays roles in normal 
aging [133, 134]. The breadth and diversity of these findings highlight the chaperone’s 
central role in protein homeostasis. Moreover, these findings suggest that chemical 
modulators of Hsp70 might find use in a wide variety of indications. 
 
1.4 Targeting the Nucleotide Binding Domain 
As mentioned above, Hsp70 is composed of multiple domains, including the NBD and 
SBD. These domains each harbor specific activities and interact with key co-chaperones. 
Thus, Hsp70 is a dynamic, multi-component machine, with numerous potential locations 
for chemical manipulation. Accordingly, the known chemical modulators of Hsp70 share 
little structural similarity and they bind multiple regions of the Hsp70 protein. In 
addition, there are a few compounds whose binding sites have not been explored [135]. 
Before discussing our efforts to characterize the human Hsp70 complexes (see Chapters 3 
and 4) and develop new screening methods for the identification of new compounds (see 
Chapter 2), it is likely useful to provide an overview of the known chemical ligands for 
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Hsp70 and what is known about their mechanisms of action. 
 
1.4.1 Nucleotide mimetics   
Compounds that compete with ATP for binding to Hsp70 would be expected to have 
significant effects on chaperone function, as this turnover is required for many of its 
activities. By analogy, many of the successful Hsp90 inhibitors, which have been 
informative in mechanistic and therapeutic studies [136, 137], are ATP-competitive. 
Thus, compounds that displace ATP from Hsp70 are also expected to be powerful tools 
[73]. Unlike Hsp90, Hsp70 binds to nucleotide using the actin-like fold, so compounds 
that bind Hsp90’s ATP-binding sites are not cross-reactive. To solve this problem, 
Williamson et al. recently designed and synthesized adenosine-derived molecules based 
on the X-ray crystal structure of a commercially available ATP analog in complex with 
Hsc70/Bag1 [138]. Several rounds of SAR studies afforded molecules with affinity for 
Hsp70 that are comparable to that of ATP; for example, compound 1 showed an IC50 of 
0.5 µM by a fluorescent polarization assay and a KD of 0.3 µM by surface plasmon 
resonance (Figure 1.4). Consistent with a role for Hsp70 in cancer cell viability, this 
compound also exhibited a GI50 of 5 µM against human colon tumor (HCT) 116 cells and 
caused degradation of the Hsp90 clients, Her2 and Raf-1. Following the logic that Hsp90 
inhibitors have been useful probes, it seems likely that these Hsp70-directed compounds 
will also be important reagents in the arsenal. Of course, further studies on their 
selectivity and potency are needed – which will be a recurring theme in these discussions, 
as the development of Hsp70-targeted compounds is a field in its relative infancy. 
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1.4.2 (-)-epigallocatechin gallate (EGCG) 
EGCG is a naturally occurring polyphenolic flavonoid that has various biological 
activities, including its functions as an antioxidant. Among these functions, it has also 
been shown to interact with the ER-resident Hsp70, BiP, by affinity chromatography 
[139]. Subsequently, the binding site was localized to the NBD using deletion constructs 
and it was shown to compete with ATP for binding. Although the selectivity of this 
compound is uncertain, it was shown to enhance the apoptotic activity of etoposide, 
consistent with a role for BiP in pro-survival signaling.  Thus, one of the pleiotropic 
activities of EGCG in cancer cells might involve partial inactivation of Hsp70 function. 
In support of this model, another flavonoid, myrectin, has recently been reported as an 
inhibitor of this chaperone[140]. This compound inhibits Hsp70’s ATPase activity (IC50 
~ 10 µM) and initiates Hsp70-mediated degradation of the Alzheimer’s disease-related 
substrate, tau. Over-expression of Hsp70 significantly enhanced the potency of myrectin 
in cell-based models, consistent with this chaperone being a target. It remains to be seen 
whether more selective compounds can be developed, based on these studies and the 
polyphenol structure. 
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1.4.3 MKT-077   
The NBD is also thought to be the site of action of MKT-077, a cationic dye with 
selective toxicity against cancer cells. Using a pull down assay, Wadhwa, et al. first 
showed that the molecule binds to mtHsp70 [141]. The same group also localized the 
binding site to the NBD using deletion mutants [142]. Interestingly, the binding site of 
MKT-077 overlapped with that of p53, suggesting that it might disrupt p53-mtHsp70 
interactions and influence apoptotic signaling [143]. Selectivity wasn’t reported, but the 
‘drug-like’ nature of this scaffold warrants further investigation.  
 
1.4.4 Sulfoglycolipids 
In binding assays, sulfogalactoglycerolipid (SGG) and sulfoglactosylceramide (SGC) 
were identified as having affinity for the testis-specific Hsc70 [144]. Using domain 
deletions and site-directed mutagenesis, the binding site was determined to reside in the 
NBD [145]. These compounds were also found to bind Hsc70s from numerous 
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organisms, highlighting the potential problem of isoform selectivity in this highly 
conserved family. Interestingly, these compounds did not affect the Km  of ATP turnover 
but they did decrease Vmax, suggesting a noncompetitive mechanism. Further structural 
studies will be required to understand whether these compounds operate by an allosteric 
binding site. However, such studies seem worthwhile, as a derivative of SGC, 
adamantylSGC, inhibited the ATPase activity of bovine brain Hsc70, a potential target in 
neurodegenerative disease [146]. Because of the similarity of these compounds to 
endogenous glycolipids, it is also interesting to hypothesize that they might be taking 
advantage of intrinsic regulatory mechanisms (e.g. mimicking interactions between 
Hsp70 and signaling lipids) [147]. 
 
1.4.5 Dihydropyrimidines   
Because ATPase activity appears to be important for many chaperone functions, screens 
for this activity have been useful tools for identifying new inhibitors and activators [15]. 
In one screen of a subset of the NCI drug collection, NSC 630668-R/1 (R/1) (Figure 1.4) 
was identified. R/1 inhibits the endogenous and J-domain protein stimulated ATPase 
activity of both Ssa1p and BiP and it also blocked Hsp70-dependent protein translocation 
[148]. R/1 contains a keto-functionalized pyridine core and, based this general 
heteroaromatic structure, a more focused cheminformatic search was conducted. These 
efforts led to the testing of 31 small molecules, mostly peptoid-functionalized 2-
dihydropyrimidinones generated by sequential Biginelli and Ugi reactions. This pilot 
library was screened for the ability to modulate the endogenous and J-protein stimulated 
ATPase activity of recombinant Ssa1p. From these efforts, compounds such as MAL3-
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101 (Figure 1.4) were identified as specific inhibitors of J-domain protein stimulated 
Hsp70 activity. Conversely, MAL3-90 and related compounds enhance the endogenous 
ATPase activity but inhibit J-domain co-chaperone activity [149]. Thus, compounds from 
this class are able to modulate ATP turnover in either direction. Given the complexity of 
Hsp70 biology, access to both classes of compounds may be fortuitous. In support of this 
idea, dihydropyrimidines are able to tune Hsp70-mediated luciferase folding activity in 
either direction [150]. Following these initial studies, a focused library of functionalized 
dihydropyrimidines was assembled by microwave-assisted, in situ Biginelli 
cyclocondensation at the terminus of a resin-bound β-peptide. A series of di and 
tripeptides with a range of hydrophobic and polar side chains were utilized to explore 
SAR in a DnaK ATPase assay [22, 150]. These results confirmed that 
dihydropyrimidines operate as either stimulators or inhibitors, depending on their context. 
Members of this collection also showed some homolog-specific modulators, as 
compound 14 inhibited bovine Hsc70 but not DnaK [151]. Finally, hydrophobic groups 
pendant to the dihydropyrimidinone core were found to be important for activity. 
 
Although the potency of these compounds is not yet optimized (variable IC50 ~ 10-200 
µM), representatives of the class have been shown to possess interesting biological 
activities. Compound SW02 (Figure 1.4), which stimulates ATPase activity, was shown 
to enhance the ability of Hsp70 to block aggregation of amyloid beta, an important target 
in Alzheimer’s disease target [152]. In another model, analogs of MAL3-101 were shown 
to inhibit proliferation of SK-BR-3 cell cancer cells, presumably by modulating the anti-
apoptotic functions of Hsp70 [153]. A similar derivative, MAL2-11B, was shown to 
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inhibit the activity of a viral J-domain protein, T antigen. This activity was associated 
with a block in viral replication in a plaque assay, suggesting that MAL2-11B may 
represent a new class of polyomavirus inhibitors [154]. Select pyrimidinone-peptoid 
hybrid compounds also exhibit potent effects on the malaria parasite, Plasmodium 
falciparum, and were shown to inhibit its replication in human red blood cells [155]. 
Recently, compounds from this class have also been shown to alter processing of the 
microtubule-associated protein, tau. Dihydropyrimidines SW02 and 115-7c (Figure 1.4) 
stimulate ATPase activity in vitro and they also promote Hsp70-dependent tau 
accumulation in models of Alzheimer’s disease [156]. These compounds share a halogen-
modified phenyl group and a simple, pendant carboxyl associated with the 
dihydropyrimidine core. While further inquiries likely await synthesis of more potent 
derivatives, the first-generation probes have been successfully used in a diverse collection 
of applications. 
 
1.5 Targeting the Substrate Binding Domain 
 
1.5.1 Substrate mimetics   
A number of short, antibacterial peptides, including drosocin, pyrrhocoricin and 
apidaecin, have been shown to bind E. coli DnaK [157]. These peptides are interesting 
because an analog of pyrrhocoricin exhibits broad-spectrum antibacterial activity against 
both gram-positive and gram-negative species. Competition experiments suggest that 
pyrrhocoricin (Kd ~ 50 µM) binds to DnaK at two different sites, including the substrate-
binding cleft of the SBD. Using fragments of the chaperone, another binding site was 
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identified within the C-terminal “lid” domain. The interaction between this peptide and 
DnaK inhibits ATP turnover in vitro and folding of model substrates in vivo [158], but it 
isn’t clear if these particular activities are responsible for the observed anti-bacterial 
function. Interestingly, pyrrhocoricin, failed to bind DnaK from S. aureus and it also had 
no anti-bacterial activity against this species, consistent with this chaperone as a target. In 
addition to these natural antibacterial peptides, Haney et al. synthesized peptides that 
were patterned after DnaK’s model substrate, NRLLLTG [159]. One of these peptides 
activated the ATPase activity of yeast Hsp70 Ssa1p by 10% at 300 µM and modeling 
confirmed that this compound could occupy the SBD cleft. The stereochemistry of this 
peptide was important for function, as the opposite diasteromer was inactive. Together, 
these studies indicate that targeting the substrate-binding pocket is an effective strategy 
for manipulating chaperone function. Another interesting observation in these studies was 
that pyrrhocoricin had no activity against human Hsc70, suggesting that this binding site 
might be leveraged to gain selectivity. 
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1.5.2 Geranylgeranyl acetone (GGA)     
GGA (Figure 1.5) induces the expression of heat shock proteins and this compound has 
been used to activate the stress response [160, 161]. For many of the pharmacological 
inducers of the stress response, such as celasterol, their molecular mechanisms are only 
beginning to emerge [162, 163]. In an attempt to explore how GGA operates, this 
compound was immobilized onto Sepharose and potential cellular targets identified by 
mass spectrometry. Interestingly, the major protein was found to be Hsp70 itself [164]. 
Subsequent experiments using truncated domains of Hsp70 suggest that the binding site 
of GGA is within the SBD, but it still isn’t clear why this interaction leads to a stress 
response. The similarity between GGA and the endogenous lipid modifications found on 
some proteins, such as farnesyl and geranylgeranyl groups, raises the interesting 
possibility that Hsp70 might natively recognize these post-translationally modified 
substrates, but this hypothesis has not been thoroughly explored. Moreover, like many of 
the scaffolds, there has not been much chemistry performed on GGA or its derivatives, so 
its utility as a drug lead is largely unexplored.  
 
1.5.3 Acyl benzamides 
In addition to their ATPase activity, Hsp70s are known to possess amide peptide bond 
cis/trans isomerase (APIase) activity [165]. This activity was specifically targeted by 
Liebscher et al., who designed and synthesized fatty acyl benzamides, consisting of three 
chemical moieties; a fatty acid, an aromatic linker and an amino acid residue (Figure 1.5) 
[166]. One of these compounds inhibited the APIase activity of DnaK with an IC50 value 
of 2.7 µM and bound with a Kd of 2.6 µM. The compound also inhibited the chaperone-
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mediated refolding of denatured firefly luciferase with an IC50 value of 9.5 µM. This 
compound was shown to compete with a model peptide for binding to DnaK, suggesting 
that it binds to the SBD. This compound was also tested for its antibacterial activity 
against E. coli and it was shown to decrease viability at a nonpermissive temperature (42 
°C) with an MIC of ~380 µg/mL. This action mirrors the failure of dnakΔ strains to grow 
at elevated temperatures, consistent with this chaperone as a cellular target.  Also 
consistent with anti-Hsp70 functions, SDS-PAGE experiments showed a significant 
increase in the amount of insoluble protein in the treated cells. To explore the potential of 
the acyl benzamide scaffold as a drug lead, the SAR was explored using both DnaK’s 
APIase activity and antibacterial potency as indicators. Variations in the fatty acid 
moiety, including the number of carbons and unsaturations, impacted inhibition of DnaK 
in vitro, but the SAR did not correlate well with antibacterial activity. Although 
substitution on the benzoic acid linker did not influence the activity against DnaK, 
positional changes in the substituent significantly increased its MIC value, suggesting 
that antibacterial activity may involve targets in addition to DnaK. However, it is 
important to note that Hsp70 is a complex machine and the relationships between APIase 
activity and other in vivo functions are uncertain. To better understand this relationship, 
the focused collection was examined for effects on chaperone-mediated refolding of 
firefly luciferase, but again changes in the acyl benzamide structure had a dramatic 
influence on antibacterial activity but dissimilar effects on substrate folding efficiency. 
Together, these data show that acyl benzamides inhibit the refolding and APIase 
activities of DnaK and the growth of E. coli although their correlation remains to be 
elucidated. However, despite some mechanistic questions, these acyl benzamides appear 
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to be promising anti-bacterial leads. It will be interesting to see if they have selectivity for 
prokaryotic Hsp70 isoforms and whether they might be used in other systems to 
manipulate APIase and chaperone functions.  
 
1.5.4 Spergualin Derivatives 
The natural product spergualin was first identified as an antibiotic from culture filtrates of 
Bacillus laterosporus BMG162-aF2 [167]. Subsequently its structure was determined to 
be (15S)-1-amino-19-guanidino-11,15-dihydroxy-4,912-triazanonadecane-10,13-dione 
and only the (-)-spergualin enantiomer was found to be active. The Umezawa group 
accomplished the first total synthesis of spergualin and its analogues by the acid-
catalyzed condensation of ω-guanidino alkanamides with glyoxyloylspermidine. They 
showed that both the carbon chain length in the polyamine region and the 15-hydroxyl 
group affected activity [168, 169]. Using these compounds in T-cell assays, they focused 
on (-)-15-deoxyspergualin (DSG) (Figure 1.5) as a potent immunosuppressive agent 
[170]. To identify the cellular targets of DSG, human T-cell lysates were analyzed by 
affinity chromatography using Sepharose beads covalently coupled to methoxy-DSG 
[171]. Using Western blotting and peptide sequencing, the interacting protein was 
identified to be Hsc70. This interaction was further characterized through affinity 
capillary electrophoresis to obtain binding affinities for purified Hsc70 (Kd = 4 µM). 
Further studies revealed that DSG and its analogs stimulate the ATPase activity of Hsc70 
(~2-fold; Km = 3 µM), but had no effect on stimulation by J-domain co-chaperones or on 
the release of substrate [172]. To further clarify the binding site of the compound, 
14
C-
DSG was cross-linked to purified bovine Hsc70 by addition of EDC (1-ethyl-3-(3-
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dimethoxyaminopropyl)-carbodiimide). Interestingly, mass spectrometry analysis of the 
resulting peptide fragments localized the binding site to the C-terminal amino acids, 
EEVD, which is the same site of binding to the TPR-domain co-chaperones. Consistent 
with this binding site, DSG was also found to bind Hsp90 with an affinity of 5 µM [173].  
 
DSG is likely the Hsp70 modulator with the best-characterized clinical utility. Although 
DSG was originally identified as a potential anti-bacterial agent, it also has anti-tumor 
activity and it has found clinical use in organ transplantation and autoimmune diseases 
[174-176]. DSG prolongs survival time after allogenic graft and minimizes acute 
rejection. Unfortunately, its mechanism-of-action is poorly understood and the potential 
roles played by its Hsp70/90 binding are unclear. One possibility arises from 
observations that DSG interferes with antigen processing/presentation by monocytes, 
which is an Hsp70-dependent process [177]. Alternatively, DSG has been found to block 
B cell development by inhibiting the nuclear translocation of transcription factor NF-κB 
[178], another activity that may involve Hsp70 and Hsp90. Similarly, it was shown that 
DSG kills the malaria parasite by interfering with the trafficking of essential proteins 
[179]. Unlike other immunosuppressive agents, such as FK506 and cyclosporin A, DSG 
does not suppress cytokine production (IL-1, IL-2) but does inhibit cytotoxic lymphocyte 
(CTL) induction [180]. Consistent with this model, DSG prophylaxis with FK506 
improves long-term graft survival in renal transplant patients [181]. Unfortunately, DSG 
has a very low bioavailability (<5%) and is very unstable in aqueous solution because of 
its labile hydroxylglycine group. To address this issue, Renaut et al., developed an 
alternative synthetic route in which this group was substituted by a malonyl unit. In a 
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graft-versus-host disease (GVHD) model in mice, these derivatives were found to be 
significantly more stable, although the SAR around the spermidine moiety is restricted 
[182]. One of the lead compounds, LF 15-0195, was less toxic and more potent than DSG 
in a renal allograft rejection primate model, suggesting that further chemical optimization 
might improve the performance of these compounds [183]. Thus, the strong biological 
data around these compounds make a case for further development. At the same time, 
there are many uncertainties in their molecular mechanism-of-action and there are 
pharmacological hurdles to overcome.  
 
1.6 Targeting the Co-Chaperones 
 
1.6.1 J-protein substrate mimetics      
As discussed above, J-domain proteins deliver substrate peptides to Hsp70 and stimulate 
ATP turnover. Consistent with the importance of these functions, Bischofberger et al. 
reported that D-peptides targeting E. coli DnaJ inhibit chaperone-dependent luciferase 
refolding in vitro [184]. The peptides were further shown to inhibit DnaJ stimulated 
ATPase activity of DnaK, which genetic studies have shown to be critical under 
physiological conditions. These compounds are thought to compete with natural 
substrates for binding to DnaJ, thus preventing its capacity to engage in productive 
interactions with the chaperone complex. These results highlight one of the interesting 
aspects of Hsp70 as a target; compounds might impact Hsp70 functions indirectly via the 
essential co-chaperones. Such approaches might be expected to have lower toxicity and 
greater selectivity, although this model remains to be tested. 
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1.6.2 Inhibitors of the TPR domain    
Another strategy that has been reported recently is direct targeting of the TPR-domain. 
Using an AlphaScreen high-throughput approach, Yi and Regan identified 
pyrimidotriazinediones that interfere with the Hop-Hsp90 interaction [185]. These 
compounds were toxic to WST-1 cells in vitro, consistent with an important role for this 
contact. In theory, a similar route could be used to develop selective inhibitors that 
decouple this class of co-chaperones from their contact with Hsp70. 
 
1.7 Concluding Remarks 
Hsp70 regulates multiple aspects of protein homeostasis. As such, it has been linked to 
numerous diseases and it has been suggested as a potential therapeutic target for many 
indications. Genetic and biochemical studies support this model and limited 
pharmacological findings have also provided intriguing insights. However, the discovery 
of potent, selective and well-characterized Hsp70 modulators remains an on-going task. 
Given recent clinical success with other proteins in the proteostasis network, such as 
Hsp90 or the proteasome, aggressive pursuit of Hsp70 seems worthwhile. The challenge 
will be to identify potent and selective chemical scaffolds. 
 
In this Chapter, we have focused on the interesting structural biology of Hsp70 and its 
many co-chaperones and how these complexes might provide unique opportunities for 
drug discovery. Specifically, Hsp70 operates as part of a combinatorial, multi-protein 
complex, with protein-protein interfaces, allosteric sites, a catalytic center and a distinct 
substrate-binding cleft. Partly owing to this structural and regulatory complexity, many 
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different chemical scaffolds have been reported to interact with Hsp70 and their binding 
sites are spread across the chaperone’s surface. Importantly, many of these first-
generation compounds have biological activities and both activators and inhibitors appear 
to have useful applications. While the complexity of Hsp70 makes it a challenging target, 
the same complexity also creates opportunities to design molecules with interesting 
capabilities. Based on the limited evidence collected thus far, we suggest that the ultimate 
toolbox of Hsp70-targeted compounds will include compounds that operate at distinct 
sites. Moreover, each disease system might require a specific Hsp70 modulator that tunes 
the proteostasis boundary to the desired and appropriate level. Thus, the goal of this 
pharmacological intervention will be to restore balance to the system and the number and 
diversity of chemical probes may need to mirror the complexity of the biology. In the 
remaining Chapters of this thesis, we will explore efforts towards this goal. 
 
 
 
Notes 
This Chapter is based on a manuscript by Srikanth Patury, Yoshinari Miyata and Jason 
Gestwicki that was published as “Pharmacological Targeting of the Hsp70 Chaperone” in 
Current Topics Medicinal Chemistry. 2009; 9(15): 1337-1351 
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Chapter 2 
 
‘Gray Box’ Screening Strategies For Targeting Hsp70 Chaperone Complexes 
 
 
2.1 Abstract 
As discussed in Chapter 1, Heat shock protein 70 (Hsp70) is a molecular chaperone that 
plays multiple roles in protein homeostasis. In these tasks, the activity of Hsp70 is shaped 
by its interactions with co-chaperones, such as the J-domain containing Hsp40 proteins 
and nucleotide exchange factor (NEF’s). To identify chemicals that target these critical 
protein-protein interactions, we devised a novel approach termed “gray-box” screening, 
in which we performed high throughput chemical screens against reconstituted 
components of the prokaryotic Hsp70 chaperone family (DnaK/DnaJ/GrpE). Using this 
approach we identified myricetin, which specifically inhibits the DnaK/DnaJ complex, 
and pancuronium bromide, which selectively inhibits the DnaK/GrpE complex. We also 
identified a series of dihydropyrimidines that either promote or inhibit the interaction 
between Hsp70 and a J protein co-chaperones. Based on this interesting activity, we 
further characterized one representative dihydropyrimidine, 115-7c. Both in vitro and in 
yeast, we found that the activities of 115-7c mirrored those of a J-domain co-chaperone; 
it stimulated ATPase and protein-folding activities and partially compensated for a loss-
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of-function mutation. NMR and mutagenesis studies suggest that the 115-7c binding site 
is adjacent to the region required for J-domain-mediated stimulation. Interestingly, the 
artificial and natural partners do not compete for binding and, rather, they act in concert, 
suggesting that 115-7c accesses a parallel allosteric conduit at the protein-protein 
interface. The unusual mechanisms of this suite of pharmacological agents may provide 
unexpected opportunities for exploring the logic of protein quality control. Further, these 
results show how “gray box” screening can be used to identify compounds that act on 
allosteric pathways in multi-protein complexes. 
 
2.1.1 Co-chaperones regulate the activity of Hsp70 
Heat shock protein 70 (Hsp70) is a member of a ubiquitously expressed family of 
molecular chaperones that are involved in protein homeostasis. In its role as a central 
mediator of protein fate, this chaperone has been linked to multiple tasks, including 
primary protein folding, subcellular trafficking, protein aggregation, proteasome-
mediated degradation and autophagy[1]. In these various tasks, Hsp70 physically 
interacts with the exposed hydrophobic residues of peptides via its C-terminal substrate-
binding domain (SBD). In turn, Hsp70’s N-terminal nucleotide-binding domain (NBD) 
regulates this interaction; hydrolysis of ATP in the NBD propagates an allosteric change 
in the SBD, which controls the position of a helical “lid” and enhances substrate affinity 
~ 10-fold [2]. Thus, although the molecular mechanisms are still unclear, ATPase activity 
is believed to be a critical determinant of chaperone structure and function. 
 
A family of associated co-chaperones, including nucleotide exchange factors (NEFs) and 
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J-domain containing proteins (also called Hsp40s), regulate the ATPase activity of 
Hsp70. For example, the ATP turnover rate of bacterial DnaK (Hsp70 family) is 
stimulated ~7-fold by the J-domain containing factor, DnaJ [3, 4]. Recent structural and 
mutagenesis studies have suggested that J-domains control enzymatic activity via 
interactions within the IA and IIA sub-domains in the NBD of DnaK [5]. More 
specifically, the residues important for this partnership are ~ 18-20 Å removed from the 
nucleotide-binding cleft, suggesting that the J-domain controls ATPase activity through 
allostery[6]. In the presence of DnaJ, ADP release becomes rate-limiting and GrpE (a 
prokaryotic NEF) assists nucleotide exchange via protein-protein interactions with the IB 
and IIB sub-domains [7]. Thus, the combination of DnaK, DnaJ and GrpE efficiently 
turns over ATP and allows control over chaperone activity [4]. As detailed in Chapter 1, 
members of both co-chaperone families (Hsp40/NEFs) possess separate, intrinsic 
capabilities and/or interact with other cellular pathways to recruit Hsp70 into a variety of 
tasks. Further, members of the Hsp70, J protein and NEF families are found in virtually 
all organisms and they are highly conserved (E. coli DnaK is ~50% identical and 75% 
similar to human Hsp70). 
 
As discussed in Chapter 1, these observations suggest that one powerful path towards 
better understanding Hsp70 biology is to identify small molecules that selectively block 
allosteric communication between the co-chaperones and Hsp70. Based on strong genetic 
findings, such molecules would be expected to be able to tune chaperone activities, 
regulate ATP cycling and provide a way to understand the logic of Hsp70-mediated 
quality control.  
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2.1.2 Few selective inhibitors of Hsp70 are known 
Despite the central role of the Hsp70 chaperone family in protein homeostasis and its 
implications in various human diseases, only a handful of pharamocological targets have 
been reported in literature (summarized in Chapter 1). More importantly, the mechanism 
of these compounds is rarely well characterized. For example, one of the earliest 
compounds identified was the natural product spergualin and its derivatives, such as 15-
deoxyspergualin (DSG), which bind Hsc70 and stimulate ATPase activity [8, 9]. Based 
on structural similarity to DSG, the Brodsky group identified NSC 630668-R/1 (R/1), 
which is a polyamine that inhibits ATPase activity and also blocks Hsp70-mediated 
trafficking of polypeptides [10]. A more focused cheminformatic search based on R/1 led 
to the testing of 31 related, peptoid-functionalized 2-dihydropyrimidinones. This pilot 
library was screened for the ability to modulate the endogenous and J-protein stimulated 
ATPase activity of recombinant Ssa1p (a yeast homolog of Hsp70). From these efforts, 
compounds such as MAL3-101 were identified as specific inhibitors of J-domain protein 
stimulated Hsp70 activity. Conversely, MAL3-90 and related compounds were found to 
enhance the endogenous ATPase activity but inhibit J-domain co-chaperone activity [11]. 
Based on these initial studies, our laboratory assembled a focused library of 
functionalized dihydropyrimidines by microwave-assisted, in situ Biginelli 
cyclocondensation at the terminus of a resin-bound β-peptide. A series of di and 
tripeptides with a range of hydrophobic and polar side chains were utilized to explore 
SAR in a DnaK ATPase assay [12]. These results confirmed that dihydropyrimidines 
operate as either stimulators or inhibitors, depending on their context. Members of this 
collection also showed some homolog-specific modulators, as compound 14 inhibited 
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bovine Hsc70 but not DnaK [13]. Thus, this scaffold appeared to have interesting 
activities on the Hsp70-J protein complex, but the mechanism was not clear. 
 
More broadly, one of the major goals of the Gestwicki laboratory (and primary long-term 
goal of my thesis work) is to produce a suite of small molecules that target each of the 
various activities of Hsp70. As discussed in Chapter 1, a full complement of Hsp70 
modulators should include compounds that inhibit ATPase activity and those that 
stimulate it. Moreover, compounds should be able to either inhibit or promote 
interactions between Hsp70 and NEFs and Hsp70 and J proteins. Finally, one would like 
to understand the molecular mechanisms, binding sites and structure-activity 
relationships of these ligands. The challenge is that traditional high throughput methods 
for identifying chemical inhibitors do not typically have the versatility required to reveal 
compounds across this spectrum of activities. One might readily identify competitive 
inhibitors of ATP binding (for example), but the same screen is unlikely to reveal 
activators or compounds that act on co-chaperone activities. Thus, a major goal of this 
Chapter is to develop high throughput methods for (a) identifying compounds that act on 
various aspects of Hsp70 complexes and (b) develop ways of understanding the 
molecular mechanisms of the resulting compounds. 
 
2.1.3 Design of high throughput screens for Hsp70 
Early attempts at developing a high-throughput screen (HTS) against the ATPase activity 
of Hsp70 failed due to the relatively low ATP turnover rate and high signal to noise (from 
spontaneous nucleotide hydrolysis) ratio. In 2008, our laboratory successfully developed 
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a robust, colorometric method in 96-well plates, using malachite green reagent (MG) to 
measure the ATPase activity of DnaK. The key design optimizations were the use of high 
concentrations of ATP to reduce discovery of nucleotide-competitive inhibitors and the 
signal was enhanced by the inclusion of co-chaperone DnaJ [4]. Two graduate students in 
the Gestwicki group, Lyra Chang and Yoshi Miyata, later adopted an energy transfer 
strategy to convert the assay to 384-well format. Briefly, white 384-well plates emit 
fluorescence when irradiated at 430nm. This intrinsic fluorescence can be quenched by 
energy with the quinalidine red (QR) chromophore. Using this more sensitive assay, we 
tested 55,400 compounds against the DnaK/DnaJ complex and identified at least one new 
inhibitor [14]. This compound (3c) favored high-affinity binding of DnaK to a model 
substrate (luciferase) and it specifically blocked stimulation by DnaJ. Using this platform, 
we also screened a small natural product library (assembled from the organic extracts of 
natural spices and crude plant materials) against the DnaK/DnaJ complex. Much like the 
screen of synthetic molecules, this approach resulted in the identification of a series of 
flavinoids, including myricetin, which selectively inhibited J-stimulated ATPase activity 
by up to 75%. Interestingly, myricetin had minimal impact on either DnaK's intrinsic 
turnover rate or its stimulation by another co-chaperone, GrpE. Together, these findings 
suggest that this approach was able to identify compounds that inhibit the DnaK/DnaJ 
complex, without affecting other complexes or activities. Finally, NMR studies revealed 
that myricetin binds DnaK at an unanticipated site between the IB and IIB subdomains 
[15]. This mechanism is unexpected because myricetin’s binding site is at least 20 Å 
from where DnaJ interacts with DnaK, in a region not previously implicated in DnaJ-
mediated allostery. Thus, this work identified an unanticipated allosteric site in the 
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DnaK/DnaK complex that might be suitable for targeting [15]. 
 
2.1.4 ‘Gray-Box’ screening strategy to selectively target specific Hsp70 complexes 
We have termed this general screening approach “gray box” screening. This name comes 
from the colloquial name that is used for cell-based or animal-based phenotypic screens, 
which are called ‘black box” screens because the identification of the key biological 
target is challenging.  However, the great strength of ‘black box’ screens is that they 
include intact pathways and protein complexes in their native cellular environment. The 
reductionist approach is to use purified proteins (usually a recombinant enzyme) and 
directly screen for the inhibition of its activity. Obviously, target identification in this 
format is trivial, but purified enzymes are often not a good representation of the 
physiological activity in the cell. This strategy has proven to be extremely successful, but 
the attrition rate is very high when the “hits” are taken from the in-vitro screening 
conditions into the biologically relevant environment in the cells/animals.  
 
Based on this terminology, we developed the idea of “gray-box” screening as a term to 
describe screens performed against reconstituted protein complexes. As discussed above, 
the aim of the approach is to design screens to identify small molecules that target a 
specific protein-protein interaction in the context of its native complex. Indeed, other 
members of the Gestwicki group have shown the advantages of this feature and identified 
myricetin, dihydropyrimidines and other scaffolds that have selective activity on the 
DnaK/DnaJ complex [12]. In this Chapter, I have explored whether this concept could be 
extended to the DnaK/GrpE complexes. In addition, I have explored the binding partners 
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and mechanisms of a number of compounds identified through DnaK/DnaJ and 
DnaK/GrpE ‘gray box’ screens. Importantly, I found that this project required a number 
of steps that are not needed in reductionist (‘white box’) screens. For example, the 
biochemical activity of the reconstituted complexes must be carefully characterized prior 
to the HTS effort and additional deconvolution steps are needed following the primary 
screens to understand the mechanisms of the active compounds. The major findings of 
this Chapter are that the concept of ‘gray box’ screening appears general and that 
compounds identified through this process have interesting activities at allosteric sites in 
the DnaK/DnaJ/GrpE complex. 
 
More generally, we propose that the concept of ‘gray box’ screens might have general 
use in other biological systems. The key design feature of the screen would be multiple 
components of the target protein complex are purified and re-constituted in vitro. The 
target protein would usually have the measurable enzymatic activity, while the other 
components would regulate the readout. In addition, protein-protein interactions between 
the protein target and its partners might mask some potential drug-binding sites, and at 
the same time induce conformation changes that might reveal other, latent sites. 
 
2.2 Results 
 
2.2.1 Concentration of the components in the reconstituted complex influences the 
identity of the “hit compounds” 
As a model system, we focused on the Escherichia coli DnaK protein. As discussed 
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earlier, the nucleotide turnover by DnaK is tightly controlled by its co-chaperones, 
including DnaJ and GrpE and also by the binding of its client substrate. Because ‘gray 
box’ screens require the reconstitution of a multi-protein complex, we first purified each 
of the three components, synthesized a model DnaK substrate, NRLLLTG (termed NR 
peptide), and characterized the effects of these factors on ATP turnover [16] (Appendix 
2.1). Specifically, we were interested in the co-chaperone concentration that yielded half-
maximal stimulation (J
’
m , E
’
m , Pep
’
m ) and maximal stimulation (J
’
sat , E
’
sat , Pep
’
sat ) in 
the malachite green ATPase (MG) assay.  In most reductionist high throughput screens, 
the assay conditions are chosen to maximize the signal:noise ratio to ensure an optimal Z’ 
score (statistical measure of the quality of the screen). However, we hypothesized that the 
relative concentration of the regulatory co-chaperone should instead be tuned to permit 
identification of compounds that could either activate or inhibit activity, which might be 
best accomplished by setting the co-chaperone level to near the half-maximal level 
instead of saturation. To test this idea directly, we screened the natural product (NP)-
library against the DnaK complexes under two different concentrations of the co-
chaperone: the apparent half-maximal and saturating concentrations (Figure 2.1).  
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The ATPase HTS effort was performed as previously described [14]. We found that the 
number of active compounds (± 3 SD) varied depending on the concentration of both 
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DnaJ (J
’
m - 23 hits, J
’
sat  - 11 hits) and peptide substrate (Pep
’
m – 19 hits, Pep
’
sat – 9 hits) 
(Table 2.1). We could not achieve a good Z’ for the screen using the half-maximal 
concentration for GrpE (
 
E
’
m) so we could not analyze the concentration dependence for 
GrpE. Thus, consistent with our model, more active compounds were identified when the 
co-factor was added near its most sensitive value. This same concept will be re-explored 
in Chapter 3 when I study the more complex human chaperone system. 
 
 
 
2.2.2 Identity of the components in the reconstituted complex also influences 
screening outcomes 
Our next question is whether the identity of the co-chaperone would impact the 
selectively of the resulting active compounds. In other words, does a screen against the 
DnaJ/DnaK system produce compounds that only affect this complex and not the 
DnaK/substrate or DnaK/GrpE combinations? Our rationale is that protein-protein 
interactions are expected to mask potential  
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binding sites, while also inducing conformations in the target protein that might reveal 
new sites. Further, we considered it quite possible that some compounds would bind the 
co-chaperone, permitting selective inhibition. To formally test this concept, we screened 
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the NP library against the DnaK + DnaJ
’
m + GrpE’m. We found that, in contrast to the 23 
compounds which acted on the K + J
’
m system, only 19 compounds acted on the K + J
’
m 
+ E
’
m system. Further, the magnitude of inhibition was often reduced by adding GrpE. 
We found similar results when we added apparent half-maximal concentration of peptide 
(Table 2.1). These findings suggest that the composition of the reconstituted protein 
complex directly influences the identity and quality of the resulting active compounds. 
 
2.2.3 Selective inhibitors for a particular chaperone complex can be identified using 
a ‘gray box’ screening strategy 
The NP library that we used in these studies is enriched with modulators for the DnaK-
DnaJ chaperone system, but we also wanted to identify synthetic compounds that are 
selective to a particular protein complex. Towards that goal, we screened the MS2000 
collection of bioactive compounds against two distinct chaperone complexes, DnaK/DnaJ 
and DnaK/GrpE, using the 
more sensitive QR-based, 
low volume, ATPase HTS 
assay [14]. Because we 
wanted to increase our 
odds of finding both 
inhibitors and activators, 
we chose to screen the 
library at the apparent 
half-maximal 
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concentrations of either GrpE or DnaJ (Z
’
 > 0.5 for both assays). From this collection, we 
identified 31 “hits” for the DnaK/DnaJ complex and 18 hits for the DnaK/GrpE complex 
(Figure 2.3). Of these hits, 10 hits were common to both screens. Excitingly, we also 
found 21 unique hits for the DnaK/DnaJ complex and 8 unique hits for the DnaK/GrpE 
complex. 
 
We purchased these compounds from commercial sources (Appendix 2.2) and confirmed 
them in the malachite green ATPase assay in a 96 well format. Specifically, we focused 
on three confirmed compounds Myricetin (IC50 = 35 ± 4.2 µM) against the DnaK/DnaJ 
complex and Pancuronium Bromide (IC50 = 42 ± 3.7µM) and Telmisartan (IC50 = 56 ± 
7.3 µM ) against the DnaK/GrpE complex (Figure 2.4). Myricetin had previously been 
identified by another graduate student, Lyra Chang, in her DnaK/DnaJ screens, so it was 
reassuring that it was re-identified in my studies. Consistent with her report, this 
 
compound only inhibits the DnaK/DnaJ complex with little affect on other DnaK 
complexes [15]. Pancuronium Bromide and Telmisartan inhibit the GrpE stimulation of 
56 
the ATPase activity of DnaK only upto 50%. One possible explanation maybe that these 
compounds may be inhibiting the complex allosterically.  
 
2.2.4 Pancuronium bromide selectively inhibits only the DnaK/GrpE complex 
Although previous efforts by the group had identified selective inhibitors of the 
DnaK/DnaJ complex, we hadn’t yet identified compounds with activity on the 
DnaK/GrpE complex. Thus, I focused on better understanding and validating these 
compounds. To characterize the mechanism of inhibition of pancuronium bromide (PB), 
we performed a series of ATPase 
stimulation assays.  
 
In the absence of compound, GrpE 
stimulates the ATPase activity of DnaK 
by approximately 2-fold, with a half 
maximal stimulation (GrpE
’
m) of about 
0.025 ± 0.002 uM. PB inhibited this 
stimulatory activity in a dose-dependent 
manner, and at a concentration of 50 uM 
increased the apparent half maximal 
concentration of GrpE
’
m 3-fold to ~ 0.1 ± 
0.005uM (Figure 2.5). The compound did 
not have any effect on the ability of DnaJ 
to stimulate the ATPase activity of DnaK 
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(Figure 2.5), the ‘mirror image’ of what was previously observed with myricetin. PB also 
did not affect the intrinsic ATPase activity of DnaK. Together, these results suggest that 
pancuronium bromide can specifically inhibit the DnaK/GrpE complex, without 
impacting the function of the other co-chaperones. This is an exciting finding because it 
suggests that (at least for the DnaK system) ‘gray box’ screens are indeed able to identify 
selective compounds and that the user-directed choice of the identity of the co-chaperone 
directly impacts the selectivity of the resulting compounds. Additional work is underway 
by other members of the Gestwicki group to more fully characterize the binding site and 
activity of PB. 
 
2.2.5 Characterizing 115-7c, a small molecule that modulates the DnaK/DnaJ 
protein complex 
Although we have shown that a ‘gray box’ screening strategy is a powerful way to 
identify compounds that act on multi-protein complexes, it does (as mentioned above) 
create a number of unique challenges as well. Principle among these challenges is the 
need to perform an extra round of deconvolution to understand which target is being 
bound. This issue is not commonly a problem in reductionist screens, because there is 
only one protein in the system. In ‘gray box’, however, the target could theoretically 
include the enzyme or the co-chaperone and the binding site could be far from the active 
site (as Lyra Chang had shown previously with myricetin). In this Chapter, one of my 
goals was to better characterize one of the most interesting Hsp70 modulators that has 
been identified, the dihydropyrimidines. As mentioned above, the dihydropyrimidines 
had been previously identified by the Brodsky group as acting on the DnaK/DnaJ system 
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(and the yeast orthologs; [11, 17]). Moreover, our group had shown that these compounds 
can either suppress or active J protein activity in vitro [12]. Because target identification 
and compound’s mechanism are proposed to be important aspects of ‘gray box’ screens, I 
wanted to better understand the activity of this class of compounds. 
 
Previous structure-activity studies by a postdoctoral fellow, Susanne Wisen, led to the 
synthesis of 115-7c (Figure 2.6A), which she found to stimulate the ATPase activity of 
the Escherichia coli DnaK (DnaKFL), by ~ 2-fold (Figure 2.6B). Binding of peptide 
substrates to DnaK is known to stimulate ATP hydrolysis, so our first hypothesis was that 
115-7c might enact its activity by interacting with the SBD. To test this model, we 
determined the activity of 115-7c against a truncated DnaK that lacks the SBD 
(DnaKNBD). These experiments revealed that 115-7c retained full activity against 
DnaKNBD (turnover increased ~3-fold), suggesting that it might bind somewhere in the 
NBD. We next studied the effects of 115-7c on the chaperone-mediated refolding of 
denatured firefly luciferase.  
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One of the major functions of the Hsp70 complex is to assist in protein folding and the 
chaperone-mediated re-folding of chemically denatured firefly luciferase is a common 
assay for studying this function in vitro [18, 19]. In this system, firefly luciferase was 
denatured with guanidinium hydrochloride, diluted and then treated with the prokaryotic 
Hsp70 system, comprised of DnaK with its two stimulatory co-chaperones, DnaJ and the 
nucleotide exchange factor GrpE. In this system, 115-7c potently stimulated chaperone-
mediated refolding activity by ~2-fold (Figure 2.6C). Together, these results indicate that 
the dihydropyrimidine, 115-7c, stimulates both ATP turnover and protein folding 
activities. Thus, this compound appeared to be a good probe for my mechanistic studies. 
 
2.2.6 Compound 115-7c is an artificial co-chaperone in yeast 
Because 115-7c displayed activities that were reminiscent of J-domain functions, we 
reasoned that it might act as an artificial co-chaperone in cells. To explore this idea, we 
turned to a budding yeast model in which a role for J-domain co-chaperones has been 
clearly documented[20]. Ydj1 is one of the DnaJ orthologs in yeast and the growth of a 
ydj1∆ mutant is severely compromised at elevated temperature [21, 22]. Thus, we 
hypothesized that 115-7c might be able to compensate for the loss of Ydj1 function. To 
investigate this possibility, we treated ydj1∆ cells with 115-7c (100 µM) by applying this 
compound to the solid growth media. As expected, the ydj1∆ cells grew normally at 30 
°C but failed to thrive at 34 °C. Application of 115-7c to ydj1∆ cells, however, greatly 
enhanced growth at elevated temperature (34 °C; Figure 2.7A). As an independent test of 
this idea, we also treated ydj1∆ cells with calcoflour white. This treatment impairs cell 
wall biogenesis and preferentially decreases the viability of ydj1∆ mutants[23]. Mirroring 
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the results of the thermal stress experiments, 115-7c (100 µM) partially rescued this 
phenotype (Figure 2.7B). We found these cell-based results particularly striking because 
we are unaware of similar genetic loss-of-function alleles that can be functionally 
recovered by synthetic mimetics. However, it is worth noting that 115-7c was 
incompletely capable of replacing Ydj1p and relatively high quantities of the small 
molecule were required, as might be expected because of the small size of the compound 
(~400 Da) compared to the full length co-chaperone (40 kDa). 
 
 
 
61 
2.2.7 115-7c binds to the IIA subdomain of DnaK 
To better understand the molecular mechanisms by which 115-7c stimulates ATP 
turnover and partially compensates for ydj1∆ phenotypes, we collaborated with Prof. Erik 
Zuiderweg (Dept. Biol. Chem.) to perform nuclear magnetic resonance (NMR) 
experiments on DnaKFL. In these experiments, 
1
H-
15
N labeled DnaKFL (500 µM) was 
titrated with 115-7c and the
 
TROESY spectra were collected (Figure 2.8A). In this assay, 
we observed a small number of chemical shifts in the presence of 115-7c and these 
signals clustered to the IIA subdomain of the NBD (Figure 2.8B). No significant changes 
were observed in the SBD.  
 
 
62 
Based on these NMR results, we collaborated with Prof. Heather Carlson’s group to use 
Langevin dynamics simulations and induced fit docking in GLIDE to build a model of 
the 115-7c-bound complex. The lowest energy configuration inserted the compound into 
a hydrophobic cleft at the bottom of the IIA subdomain (Figure 2.8C). This model 
included a number of favorable interactions, including the juxtaposition of the carboxylic 
acid with a charged surface composed of R188 and the amide nitrogen of G186 (Figure 
2.8D). Moreover, the phenyl group was placed into a deep hydrophobic pocket composed 
of F216, I207, V192, I338 and A176. This orientation provides a model for how 115-7c 
might bind the IIA subdomain. 
 
2.2.8 115-7c and DnaJ access parallel allosteric mechanisms 
Intriguingly, the IIB and IIA regions of the NBD have been implicated in allosteric, 
interdomain communication and the stimulatory activity of J-domains [5, 24, 25]. To 
examine potential overlap between physiologically important residues in this region and 
those responsive to 115-7c, we first mapped both sets onto the crystal structure of 
DnaKNBD. This analysis suggested that the artificial and natural co-chaperones might 
share only partially overlapping allosteric sites (Figure 2.9A). To test the relevance of 
this model, we made point mutations in three residues (E170S, E217A and Y193A) and 
measured their responsiveness to ATPase stimulation. The E170S mutation was chosen 
because it was previously reported to be important for stimulation by J-domains [5, 6] 
and, consistent with that idea, we confirmed that Hsc70NBD (E170S) was resistant to DnaJ 
(Figure 2.9B). In contrast, 115-7c retained full activity against this mutant. Similarly, we  
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found that DnaKFL (Y193A) retained responsiveness to DnaJ but not 115-7c (Figure 
2.9B). Finally, we explored the influence of a residue that was predicted to be important 
for both J-domains and 115-7c. This mutant, DnaKFL (E217A), could be stimulated by 
the small molecule but not DnaJ, suggesting that only a subset of the residues from the 
NMR study are critical for mediating the activity of 115-7c. Importantly, although some 
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of these mutations altered the intrinsic hydrolysis rate [5], none of them impacted global 
structure, as measured by circular dichroism (Figure 2.9C). Together, these mutagenesis 
results suggest that there are at least two allosteric possibilities in DnaKNBD and that the 
artificial and native co-chaperones access parallel, but non-overlapping conduits. 
 
2.2.9 Compound 115-7c binds better to the DnaK-DnaJ complex than to DnaK alone  
Based on the structural and mutagenesis studies, we wanted to understand whether 115-
7c and DnaJ could both bind to DnaK at the same time. Towards this goal, we first 
measured 115-7c binding by isothermal calorimetry (ITC) and found that it binds weakly 
to both DnaKFL (Kd ~ 220 µM) and DnaKNBD (Kd ~ 211 µM; Figure 2.10A). Next, we 
attempted to block interactions with 115-7c using saturating levels of DnaJ. Surprisingly, 
we found that 115-7c bound ~ 2-fold better to the DnaK-DnaJ complex than the isolated 
chaperone (Kd 113 µM). Because 115-7c has no appreciable affinity for DnaJ these 
results suggest that 115-7c has a more favorable binding site on the composite DnaK-
DnaJ complex than on the DnaK protein alone. 
 
2.2.10 Converting 115-7c into an inhibitor by preventing synergy with the J-domain 
Based on these results, we envisioned a simple ternary model in which both 115-7c and 
DnaJ bind DnaK in the cleft between the IIA and IIB subdomains. Because the residues 
important for their functions are in close proximity (see Figure 2.10A), we next explored 
whether adding bulk to the small molecule could create steric clashes. In these studies, 
we focused on the dicholorobenzyl substitution on 115-7c, because this region was
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predicted to be relatively solvent exposed in the docked model and, moreover, this group 
pointed towards the J-domain responsive residues in the adjacent IIB subdomain (see 
Figure 2.8C and 2.9A). This analysis led to the design and synthesis of 116-9e, which is 
similar to 115-7c except that the dichlorobenzyl functionality has been replaced with a 
bulkier di-phenyl group. In the ATPase assay, 116-9e was a mild (~20%) stimulator of 
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the DnaK-GrpE complex, but it potently inhibited the DnaK-DnaJ complex, suggesting 
that it selectively interfered with functional coupling to the J-domain (Figure 2.10D).  To 
further explore this relationship, we titrated DnaJ into DnaKNBD in the presence of 115-7c 
or 116-9e and measured ATP turnover. In these experiments, we found that 115-7c 
enhanced coupling of DnaJ to DnaK; the half-maximal potency of DnaJ was 
approximately 2-fold better in the presence of 115-7c (Figure 2.10D). Conversely, 116-9e 
strongly suppressed J-domain-mediated stimulation of ATPase activity (Figure 2.10D). 
Together, these results suggest that 115-7c and 116-9e tune chaperone activity in the 
context of the DnaK-DnaJ complex by regulating interactions with the native co-
chaperone. Thus, a compound identified in a ‘gray box’ screen was found to have an 
unusual (and largely unprecedented) activity at a protein-protein interface. 
 
2.3 Discussion 
Our major goals in this Chapter were to better understand the design principles governing 
successful completion of ‘gray box’ screens. More specifically, we wanted to test 
whether this approach could also be used to identify inhibitors of the DnaK/GrpE system 
and whether the ratio of the co-chaperones was important in determining the screen 
results. Further, we wanted to explore biochemical and structural methods for rapidly 
performing follow-up studies that would reveal the binding partner, its binding site and 
its potential mechanisms. 
 
In this Chapter, we found that the identity of the co-chaperone does impact the chemical 
scaffolds that are identified and we collected evidence that inhibitors of the DnaK/GrpE 
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combination can be found with this approach. Together with previous work from the 
group, these findings support a model in which ‘gray box’ screens can be used to identify 
compounds that tune the activity of this complex chaperone system. More work is needed 
to improve the potency of these compounds, but the efforts described here provide a basis 
for further work in this area. In Chapter 3, we will discuss related efforts to characterize 
the human Hsp70 system and enable parallel HTS efforts. 
 
Another goal of this project was to fully characterize one promising product of ‘gray box’ 
screens: the dihydroyrimidines. We found that the stimulatory activity of 115-7c was not 
competitive with DnaJ and, in fact, these factors appeared to work together to stimulate 
ATP turnover. Based on this model, we converted 115-7c into a context-specific 
inhibitor, 116-9e, by appending steric bulk. These results help clarify how compounds 
like 115-7c might be re-assigned as either activators or inhibitors depending on the 
presence of J-domains and their chemical substitution patterns. More broadly, these 
results also establish that 115-7c and its derivatives might be used as chemical probes to 
explore Hsp70-mediated protein homeostasis.  
 
Another interesting and unexpected aspect of this study is that the small molecules appear 
to operate at a protein-protein interface to either stimulate or inhibit allosteric pathways. 
A growing number of studies have reported potent inhibitors of protein-protein 
interactions [26, 27]. In those studies, the molecules typically bind to one protein partner 
and either directly [28] or allosterically [29] block formation of the protein-protein 
complex. Our findings provide evidence that inhibitory activities at protein-protein 
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contacts are not predestined; 115-7c accesses a native protein-protein interface and 
mimics functional aspects of the natural co-factor. Thus, this chemical probe operates in a 
previously unanticipated mode at a natural interface, suggesting new avenues for 
regulating the function of multi-protein complexes. 
 
2.4 Experimental Procedures 
 
2.4.1 Protein expression and purification 
DnaK, DnaJ and GrpE proteins were expressed in E. coli BL21 (DE3) using T7-based 
vectors. DnaK and GrpE were expressed at 37 C, while DnaJ was expressed at 25 C in 
order to increase the fraction of soluble protein. All purification steps were carried out at 
4 C. Protein concentration was estimated by Bradford assay, using BSA as the standard. 
Following purification, proteins were frozen on liquid nitrogen and stored at –80 C until 
use.  
Purification of DnaK was accomplished by a modification of established procedures. 
Briefly, cell pellets were suspended in buffer A (25 mM Tris, 10 mM KCl, 5 mM MgCl2, 
pH 7.5) containing 0.01 mM PMSF and 1 mM DTT, and disrupted using a microfluidizer 
(Microfluidics). Cleared extracts were applied to a Q-Sepharose fast-flow column (GE 
Healthcare), and the protein was eluted with a 10-500 mM gradient of KCl in buffer A. 
Fractions containing DnaK were pooled and applied to ATP-agarose (Sigma). After 
extensive washing with Buffer A and Buffer A containing 1 M KCl, the protein was 
eluted with Buffer A containing 3 mM ATP. The pure protein was concentrated and 
exchanged to buffer A for storage.  
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DnaJ was purified using a streamlined version of established methodology. Briefly, cell 
pellets were resuspended in buffer B (25 mM Tris, 2 M urea, 0.1% Brij-58, 2 mM DTT, 
pH 7.5) containing 0.01 mM PMSF and disrupted using a microfluidizer. Cleared extracts 
were applied to a Source SP (GE Healthcare) column, and the protein was eluted with a 
gradient of 0-350 mM KCl in buffer B. Fractions containing DnaJ were pooled and 
applied to a hydroxyapatite (BioGel HTP, Bio-Rad Laboratories) column that had been 
equilibrated with buffer C (buffer B containing 50 mM KCl and no detergent). After 
extensive washing with buffer C and buffer C containing 1.0 M KCl, the protein was 
eluted with a 0-350 mM gradient of potassium phosphate, pH 7.4. Fractions containing 
DnaJ were pooled, diluted two-fold with 25 mM Tris, 50 mM KCl, 2 M urea, pH 9.0, and 
applied to a Q-Sepharose fast-flow column. Pure DnaJ was collected in the flow-through, 
concentrated, and exchanged into buffer A containing 150 mM KCl for storage. 
GrpE was purified as follows: Cell pellets were resuspended in buffer D (25 mM Tris, pH 
7.5) containing 0.01 mM PMSF and disrupted using a microfluidizer. Cleared extracts 
were applied to a Q-Sepharose fast-flow column, and protein was eluted with a 0-500 
mM gradient of KCl in buffer D. Fractions containing GrpE were pooled, supplemented 
with 1 M ammonium sulfate, and applied to a phenyl-Sepharose high-performance 16/10 
column (GE Healthcare). Protein was eluted with a 1.0-0 M gradient of ammonium 
sulfate in buffer D. Fractions containing GrpE were pooled, concentrated, and applied to 
a Superdex 200 26/60 column (GE Healthcare). Protein was eluted at 0.5 ml/min in 
buffer D. Fractions containing GrpE were pooled, concentrated, and the protein was 
exchanged into buffer A for storage. The protein was greater than 90% pure as judged by 
SDS-PAGE and Coomassie staining. 
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2.4.2 Screening against DnaK complexes in 384- well Format 
The QR reagent was prepared exactly as indicated above. All components other than 
compounds were added by a Multidrop dispensor (Thermo Fisher Scientific, Inc., 
Waltham, MA). The DnaK-DnaJ stock solution was prepared so that the final 
concentration of DnaK was 0.4 µM and DnaJ was 0.7 µM (unless noted). This solution (5 
μL) was then added to each well of a 384-well opaque, white, low-volume, non-sterile, 
polystyrene 384-well plates (Greiner Bio-One North America Inc., Monroe, NC). To this 
solution, 0.2 μL of either compound (1.5 mM) or DMSO was added to each well by 
Biomek HDR (Beckman, Fullerton, CA). Finally, 2 μL of a 3.5 mM ATP solution was 
added to begin the reaction. The plates were then incubated for 3 hrs at 37 °C. After 
incubation, each well received 15 μL of the QR reagent, allowing 2 min of reaction time, 
and then quenched by addition of 32% w/v solution of sodium citrate (2 μL). These plates 
were incubated for 15 min at 37 °C and the fluorescence intensity measured (excitation 
430 nm, emission 530 nm) on a PHERAstar plate reader. Standard curves were obtained 
using stock solutions of dibasic potassium phosphate.  
 
2.4.3 Yeast growth experiments  
Wild-type yeast in the W303 background (MATa, leu2-3,112, his3-11, trp1-1, ura3-1, 
can1-100, ade2-1) and a ydj1∆ strain (DYJ1) (MATa, ura3-52, lys2-801, ade2-101, trp1-
Δ63, his3-Δ200, leu2-Δ1, ydj1::TRP1) were used. These cells were grown in rich media 
(YPD) at 30 °C over night, followed by dilution to equal concentrations (OD600 of 0.5). 
For the experiments performed at elevated temperature, cells were spotted in four 5-fold 
dilutions on YPD agar plates. These plates were pretreated with compound (50 or 100 
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µM, 0.5% DMSO) or 0.5% DMSO alone. The plates were grown at 34 °C for 4 days. We 
noted more dramatic growth recovery on YPD (compared to SC) but the origin of this 
difference is not clear. Alternatively, the YPD plates were pretreated with calcofluor 
white to a final concentration of 20 µg/ml, alone or in combination with 115-7c, followed 
by incubation at 30 °C for four days. 
 
2.4.4 NMR spectroscopy 
 
15
N-labeled DnaK2-605 and DnaK2-388 were expressed in standard minimal medium 
containing 
15
NH4Cl as the sole nitrogen source, using T7-based expression vectors. 
Following purification, proteins were concentrated to approximately 0.5 mM, exchanged 
into NMR buffer (25 mM Tris, 10 mM MgCl2, 5 mM KCl, 10% 
2
H2O, 0.01% sodium 
azide, pH 7.1), and stored at –80 C until use. Prior to NMR analysis, DnaK2-388 samples 
were thawed and supplemented with 5 mM ATP (ATP). Samples of DnaK2-605 were 
additionally supplemented with 2.5 mM of a high affinity peptide (NRLLLTG). After 
collecting reference spectra, 115-7C was titrated to a final concentration of 1 mM from a 
100 mM stock in DMSO. Control experiments showed that DMSO alone had had no 
detectable effects on the spectrum of DnaK2-388 at concentrations up to 1%, and that it had 
minimal effects on the spectra of DnaK2-605 at the same concentration. 2D HSQC-
TROSY NMR spectra were collected at 30 ºC on a cryoprobe-equipped Varian Inova 800 
MHz spectrometer, with data collection times of approximately 2 hours per spectrum. 
NMR data were processed using NMRPipe  and analyzed with Sparky ( UCSF).  
Combined 
1
H and 
15
N chemical shift changes were measured using a weighted function 
and the assignments generated previously.   
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2.4.5 Induced Fit Docking (IFD) 
The crystal structure of E. coli NBD (PDB: 1DKG) (Harrison 1997) was used after 
removal of the GrpE and rebuilding of the missing loops in the NBD using PyMOL 
(DeLano) and MOE (2005.06). Langevin dynamics simulations of NBD with Amber 10 
(Case 2008) and FF99SB force field (Hornak 2006) in various nucleotide-binding states 
were performed to sample relaxed, alternative conformations of the protein (manuscript 
in preparation). A snapshot of the simulations was used to perform docking. Using this 
snapshot, an IFD protocol (Sherman 2006) developed by Schrödinger (2008) was used. 
Briefly, this procedure involved four core steps: 1) generating ligand poses into the 
defined binding site by softened-potential docking; 2) refining residue side-chains near 
each ligand pose from the first step; 3) re-docking ligand into the optimized induced-fit 
structure and 4) scoring the poses by docking energy (GlideScore) and receptor energetic 
terms (Prime energy). The ligand and protein were prepared in Maestro (2007). IFD was 
initiated with a constrained minimization of the receptor. Prime loop prediction function 
of IFD was used to generate a maximum of 5 alternative loop (D208-T215) 
conformations for Glide docking. Side-chain refinement was performed to residues 
within 5.0 Å of the defined loop segment. Predicted loop structures with energy 30 
kcal/mol above the lowest-energy structure were rejected. In the first stage of docking, 
Glide docked ligand into the rigid receptor with a softened van der Waals potential. The 
grid box was centered at residue E206 (based on the NMR results) and the box size was 
determined automatically. 10 top scoring ligand poses were kept. For each initial docking 
pose, Prime performed side-chain refinement to residues that were within 5.0 Å of the 
ligand, allowing the side-chains to adopt optimal conformation to interact with the ligand. 
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Glide then re-docked the ligand into the induced-fit receptor with standard parameters 
and the final ligand poses were scored using a combination of Glide SP score and Prime 
energy. Ligand poses with ligand-receptor interaction matching the observed NMR 
chemical-shifts were accepted. 
 
2.4.6 Isothermal calorimetry 
Isothermal calorimetric(ITC) titrations were performed with a VP-ITC MicroCalorimeter 
(MicroCal, Inc., Northampton, MA) at 37 °C. Titration experiments were performed in 
25 mM PBS (pH 7.4), 5 mM MgCl2, 150 mM KCl, 5% DMSO. DnaKFL (60 µM), 
DnaKNBD (60 µM) or DnaJFL (1 mM) were extensively dialyzed and then introduced into 
the calorimetric cell (cell volume = 1.43 mL). Protein samples were then titrated with 500 
µM 115-7c in 15 µL steps until saturation was achieved. Injections were performed at 2 
µL/s. Data was analyzed using Microcal Origin (v2.9) assuming independent binding 
sites to yield enthalpy, stoichiometry of binding and association constant. As a control 
experiment, we confirmed that 115-7c does not bind to DnaJ even at 1mM 
concentrations. The weak affinities of 115-7c to DnaK and DnaK-DnaJ complex 
observed in the ITC platform need to be confirmed by NMR experiments. 
 
Notes 
Srikanth Patury and Jason Gestwicki designed the experiments. Chemical synthesis and 
yeast cell studies were done by Susanne Wisen and Chris Evans. Mutational analysis of 
DnaK was done by Andrea Thompson. NMR experiments were performed by Eric 
Bertelsen and Prof. Erik Zuiderweg. Characterization of the mechanism of 115-7c has 
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been published as ‘Binding of a small molecule at a protein-protein interface regulates 
chaperone activity in the Hsp70-Hsp40 complex.’ (2010) ACS Chemical Biology 5:611-
622. 
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Chapter 3 
 
Biochemical characterization of the Human Hsp70 chaperone complexes 
 
3.1 Abstract 
As described in Chapter 1, heat shock protein 70 is an ATPase that cooperates with its 
co-chaperones, Hsp40s (or J proteins) and nucleotide exchange factors (NEFs), to 
regulate protein quality control. Although there are only one Hsp40 (DnaJ) and NEF 
(GrpE) in most prokaryotes, these classes of co-chaperones are greatly expanded in 
higher organisms. For example, there are at least 20 J proteins in yeast and more than 40 
in humans. Based on the knowledge gained in Chapter 2, the main goal of this Chapter is 
to identify chemical probes that target the human Hsp70 chaperone complexes. Towards 
that goal, we first needed to biochemically characterized a number of distinct Hsp70 
complexes, composed of 16 combinations of two human Hsp70 isoforms (Hsc70 and 
Hsp72), three representative Hsp40s (DJA1, DJA2 and Hsj1) and three major NEFs 
(BAG1, BAG2, BAG3). This part of the study provided unexpected insights into the 
specialized, biochemical functions of these human Hsp70 complexes in vitro and they 
identified previously unknown and dramatic differences between the eukaryotic and 
prokaryotic systems. For example, we found that the ATPase activity of human Hsp70s is 
not stimulated by substrates and that human NEFs, such as BAG1 and BAG2, do not 
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dramatically stimulate nucleotide exchange in steady state ATPase assays, despite both of 
these factors having good affinity for Hsp70s. Moreover, we show that the Hsp40 DJA2, 
but not its highly homologous ortholog DJA1, is able refold denatured luciferase, even 
though both DJA1 and DJA2 have similar effects on ATP stimulation. Finally, a major 
goal of this thesis is to characterize the Hsp70 systems in order to enable “gray box” 
screening (as described in Chapter 2). Thus, in the last part of this Chapter, we performed 
a high-throughput screen of 100,000 diverse compounds against a reconstituted human 
chaperone complex (Hsp72/DJA2/BAG2) and successfully identified primary “hit 
compounds”. Interestingly, some of these compounds appear to inhibit Hsp40-stimulated 
ATP turnover, suggesting that (like we saw in Chapter 2) a “gray box” strategy may be 
an effective way to find new chemical probes for this system. Together, these results 
provide promising, new chemical probes and the most systematic biochemical study of 
human Hsp70s to date. 
 
3.1.1 The human HSPA (Hsp70) family 
The human Hsp70 family consists of at least eight homologous proteins with a high 
degree of sequence conservation (~85%) [1]. Isoforms of Hsp70s are found in every 
subcellular organelle. For example, a family member is found in both the endoplasmic 
reticulum (HSPA5 or Bip) and mitochondria (HSPA9 or mtHsp70) [2, 3]. In the cytosol, 
the major isoforms are the stress-inducible HSPA1 (Hsp72) and the constituitively 
expressed HSPA8 (Hsc70). Hsc70 is considered a ‘housekeeping’ member of the family 
that is involved in folding of nascent polypeptides, protein translocation, chaperone 
mediated autophagy and other tasks and it is constitutively expressed in all cell types [4]. 
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Hsp72 is the major stress inducible isoform and it functions in enabling the cell to cope 
with aggregation denatured proteins during and after the stress [5]. 
 
3.1.2 Hsp70 chaperone complexes can select from large numbers of potential co-
chaperones in eukaryotes 
In addition to having multiple Hsp70 isoforms, mammalian cells contain over 40 Hsp40s 
(J-proteins) and at least 4 distinct types of NEFs [6]. At any given time, an individual 
Hsp70 molecule can only interact with a single representative of each major class; 
therefore tens of thousands of possible complexes are possible (Figure 1.3). Why do 
mammalian cells have so many chaperone complexes? Do they serve specific functions? 
Understanding the biochemical properties of these complexes might provide insight into 
Hsp70 biology. 
 
3.1.3 DNAJ (Hsp40s, J-proteins) family co-chaperones are diverse in humans and 
enable the multifunctionality of Hsp70 chaperones 
In the human genome, at least 41 different DNAJ-encoding genes have been identified 
[7]. The various members of this family are classified into 3 groups (A-, B- and C-type) 
based on their sub-domain architectures (described in Chapter 1 and extensively reviewed 
in [8]). The defining feature of these proteins is the highly conserved J-domain, which 
interacts with the Hsp70 and stimulates its ATPase activity [9]. In addition to the J 
domain, many DNAJ co-chaperones have other domains with distinct functions. For 
example, some A-type J-proteins have also been shown to bind client proteins and deliver 
them to Hsp70 [10]. The diversity of structures in these non-J domain regions suggests 
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that different Hsp40s may play distinct roles in Hsp70 biology. This model has been 
partially verified by genetic studies in yeast systems, in which J proteins are found to 
have some redundant and some unique activities [11, 12]. However, biochemical analyses 
and comparisons of human J proteins have been rather limited.  
 
As a first step in better understanding the biochemistry of human Hsp70 chaperone 
systems, we chose to focus on three cytosolic J-proteins, DJA1, DJA2 and Hsj1, which 
are closely related to the best-characterized yeast cytosolic protein, Ydj1 [13]. In part, we 
chose these J proteins because DJA2 has been previously shown to stimulate the ATPase 
activity of Hsp72 [14], but DJA2 was found to stimulate Hsc70-mediated refolding of 
denatured luciferase to much greater extent than DJA1 [15]. Hsj1 is an interesting J-
protein because it contains two ubquitin-interacting motifs (UIMs) in its C terminal 
region, suggesting a role in turnover. Moreover, Hsj1 can target misfolded proteins such 
as polyQ for degradation [16, 17]. Together, we hoped that this suite of J proteins would 
provide a good overview of interactions between these co-chaperones and Hsp70. 
 
3.1.4 Nucleotide Exchange Factors (NEFs) also give chaperone complexes specific 
functions 
There are four distinct classes of NEFs in the human genome and although they all 
interact primarily with the NBD of Hsp70, nucleotide release activity is achieved by 
mechanistically distinct ways (as described in Chapter 1). Briefly, the GrpE-type and 
HSP-binding protein 1 (HSPBP1) type NEF families are primarily involved in only 
nucleotide exchange [18]. In contrast, the Hsp110 class both binds to client proteins and 
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facilitates nucleotide exchange [19]. The final class of NEFs, the Bcl2-associated 
athanogene (BAG) family of proteins, appears to offer the most divergence in cellular 
functions. These six NEFs contain a variety of other domains thought to be involved in 
guiding the fate of bound substrates. For example, BAG1 contains an ubiquitin-like 
domain and it has been shown to mediate interactions between Hsp70 and the proteasome 
[20], helping to degrade raf-1 protein kinase, the glucocorticoid hormone receptor and 
mutant huntington [21]. In contrast, the related NEF, BAG2, has been identified as an 
inhibitor of CHIP that blocks proteasomal degradation [22], while BAG3 specifically 
helps with Hsp70-mediated aggresome-targeting and autophagy [23]. In this Chapter, we 
focused on BAG1-3 to better understand how they bind Hsp70s and how they impact 
ATP cycling. 
 
3.1.5 Combinatorial assembly of Hsp70 complexes and “gray box” screening 
 
One of our major goals is to identify small molecules that target the activity of specific 
Hsp70 chaperone functions. As discussed in Chapter 2, the design of ‘gray box’ screens 
requires informed choices about the identity and relative ratio of Hsp70 and its co-
chaperones used in the screen. In contrast to the prokaryotic DnaK-DnaJ-GrpE system, as 
detailed above, the diversity of the co-chaperones in the human is more complex. Thus, 
in this Chapter, we sought to characterize the biochemical properties of reconstituted 
human chaperones using the “modules” of Hsc70, Hsp72, DJA1, DJA2, Hsj1, BAG1, 
BAG2, and BAG3. Specifically, we characterized their ATP turnover rates, binding 
constants of the components for each other and explored how they differ in their ability to 
refold a model substrate in vitro. Guided by this knowledge, we designed and 
85 
implemented a HTS campaign against Hsp72-DJA2-BAG2 and found new inhibitors. 
 
3.2 Results 
 
3.2.1 Human Hsp70s (Hsp72 and Hsc70) have similar ATPase and holdase activities 
compared to E. coli DnaK  
Towards our goal of characterizing the human Hsp70 chaperone system, we 
recombinantly expressed and purified the Hsc70 and Hsp72 chaperones and the DJA1, 
DJA2, Hsj1, BAG1, BAG2 and BAG3 co-chaperones. In the first set of characterization 
studies, we measured the intrinsic ATPase activity of the human Hsp70s by malachite 
green (MG) assays and compared them to the well-known DnaK protein (see Chapter 2). 
These results suggested that the human chaperones had similar intrinsic ATP hydrolysis 
rates to each other (~1.4 ± 0.3pmolPi/µg chaperone/min) (Figure 3.1A) and that both 
rates were similar (or slightly reduced) compared to DnaK (~1.7 ± 0.23pmolPi/µg 
DnaK/min). We also wanted to verify our recombinant Hsp70s bound to luciferase 
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using a “holdase” assay. In this assay, the ability of a chaperone to protect luciferase from 
heat denaturation is measured (see Experimental Procedures). We found that both Hsp72 
(12.7 x 10
3
 lum) and Hsc70 (12.1 x 
10
3
 lum) were able to protect firefly 
luciferase from unfolding, but that 
these activities were slightly reduced 
compared to DnaK (15.1 x 10
3
 lum) 
(Figure 3.1B). These rather modest 
differences between DnaK and the 
human Hsp70s was not statistically significant and could be due to small differences in 
folding. 
 
3.2.2 Substrate peptide does not 
stimulate the ATPase activity of human 
Hsp70s 
Binding of substrate in the substrate 
binding domain (SBD) of DnaK induces an 
allosteric conformational change that 
stimulates ATP hydrolysis in the NBD 
[24].  In addition, it has also been shown 
that ATPase rates correlate to substrate 
binding affinity [25]. These findings have 
been used to propose that substrates 
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control, in part, their own fate in the DnaK-DnaJ-GrpE system by allosterically 
stimulating nucleotide hydrolysis. To test if this same model holds true in human Hsp70s, 
we performed ATPase assays in the presence of the well-characterized chaperone 
substrate, NRLLLTG (NR) peptide. We were surprised to find that NR-peptide clearly 
did not stimulate the ATPase activity of either Hsp72 and Hsc70. This is a major and 
potentially significant difference between the eukaryotic and prokaryotic systems 
 
To verify this unexpected result, we wanted to confirm that the NR peptide binds to the 
human chaperones. Using immobilized Hsp70s in a bio-layer interferometry (Octet Red) 
system, we found that NR-peptide binds to the human chaperones (Kd = 17.7 ± 1.4 µM) 
at only a 4-fold weaker affinity compared to DnaK (Kd=3.76 ± 0.3 µM). Satisfyingly, the 
affinity of NR peptide for DnaK by Octet Red was similar to the affinity published 
previously (Kd = 11 µM) by ITC [24, 26]. Thus, differences in affinity are not sufficient 
to describe why substrate doesn’t stimulate ATP hydrolysis in human Hsp70s. Rather, 
differences in allostery may be involved.  
 
3.2.3 Different co-chaperones are able to support different levels of ATPase 
stimulation in human Hsp70s 
As discussed in Chapters 1 and 2, DnaK’s co-chaperones DnaJ and GrpE stimulate steady 
state ATPase activity through their ability to stimulate hydrolysis and exchange, 
respectively. Using parallel logic, we wanted to characterize the human J-proteins (DJA1, 
DJA2 and Hsj1) and NEFs (BAG1, BAG2 and BAG3). Specifically, we tested ~12 
distinct Hsp70 complexes formed from combinatorial reconstitution of these co-
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chaperones in MG assays (Table 3.1 and Appendix 3.1). These results are plotted as 
surface diagrams in which the Hsp70 concentration is held constant and the levels of one 
J protein and one NEF is varied. 
 
. 
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The full description of this data is found in the Appendix, and the results in Figure 3.4 are 
representative of what we found. Specifically, we saw that the different J-proteins were 
able to stimulate the ATPase activities of both Hsp72 and Hsc70 (Figure 3.4 and 
Appendix 3.1), but that they had different “potency”, as described by their half-maximal 
concentrations required for stimulation (Figure 3.4 and Table 3.1). DJA1 and DJA2 had 
similar Km values of (~0.5µM) against both Hsp72 and Hsc70, while Hsj1 had a higher 
Km value of (~4. 5µM). All of the human J proteins had the same maximum stimulation 
value (Vmax ~18 pmol ATP/µg/min), suggesting that only the affinity of the different J 
proteins might be different. Surprisingly, none the NEFs had any stimulatory affect. This 
is surprising because GrpE stimulates 2-6 fold under these conditions.  Thus, human 
Hsp70/NEF systems also differ from the prokaryotic. We note that these experiments do 
not rule out an effect in single turnover assays or under conditions of specific substrates 
or J combinations. 
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3.2.4 Only DJA2 can stimulate the in vitro refolding capacity of Hsc70/Hsp72 
One of the functions of Hsp70s is to refold damaged proteins, and this activity can be 
measured in vitro by luciferase refolding assays. In the prokaryotic system, full refolding 
of denatured luciferase requires all three components and the process is absolutely 
dependent on DnaK and DnaJ 
[27]. We tested the 12 
different human Hsp70 
combinations and found that 
only DJA2 supported 
refolding in combination with 
either Hsc70 or Hsp72 
(Figure 3.5 and Appendix 
3.2). In a very interesting 
finding, none of the other co-
chaperones was able to 
support refolding (e.g. see 
Figure 3.5B). Again, this 
result is in stark contrast to 
the prokaryotic system and it 
reiterates the functional 
complexity of the human 
chaperone system. 
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3.2.5 Human NEFs bind directly to human Hsp70s 
It was somewhat surprising to us that the human BAG-type NEFs were not able to 
stimulate either ATP turnover or the refolding capacity of Hsp70s. Next, we wanted to 
determine whether or not these proteins bind to Hsp70s. If they didn’t bind to Hsp70s, 
then they might be partially unfolded or otherwise damaged, which might explain why 
they didn’t assist ATPase or refolding activity. Circular dichroism studies conformed that 
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the BAGs appeared folded, but to further clarify this issue, we develop a flow cytometry-
based binding assay to measure the binding affinities of the BAG1-3 proteins to Hsp70 
(Figure 3.6). 
 
Briefly, biotinylated Hsp70 is loaded onto streptavidin coated microspheres and 
incubated with BAG protein that had been labeled with a fluorophore (AlexaFluor488). 
Both the Hsp70 and BAG protein were labeled with amine reactive probes and the free 
probe was removed, as described in the Materials and Methods. We then measure the 
bead-associated fluorescence to determine apparent binding constants. Importantly, beads 
coated with biocytin served as the negative control to account for non-specific binding. In 
these studies, we observe a dose-dependent binding with both BAG2 (Kd 122 ± 3.6 nM) 
and BAG3 (Kd 39.1 ± 3.6 nM) (Figure 3.6B). To confirm that the observed binding event 
is specific we competed with unlabeled BAG (BAG2 IC50 = 12.7 ± 1.6µM, BAG3 IC50 = 
423.7 ± 23.6 nM). These binding affinities have recently been verified by another 
graduate student, Jennifer Rauch, using isothermal calorimetry (ITC). In addition, Ms. 
Rauch found that BAG1 binds Hsp70 with an affinity of 212 ± 19.8nM (preliminary 
results). Thus, we conclude that the BAG proteins bind Hsp70, but they are not potent 
nucleotide exchange factors or stimulators of luciferase refolding in vitro. Rather, they 
may serve as scaffolding proteins to recruit Hsp70 to subcellular locations or into specific 
partnerships. 
 
3.2.6 Gray Box screen against the human chaperone complex (Hsp72/DJA2/BAG2)  
The biochemical characterization of the human Hsp70 systems (described above) 
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suggested that a screen against human Hsp70 systems may yield sufficient signal:noise 
for high throughput chemical screening. Next, we considered which specific complex we 
should use in the screen. Because DJA2 was active in the ATPase assays and it was the 
only human J protein with functional refolding activity, this co-chaperone seemed like a 
clear choice. Based on what we learned in the biochemical characterization studies and in 
Chapter 2, we used DJA2 near its Km value (Appendix 3.3), to increase the odds of 
finding activators. The two human Hsp70s, Hsp72 and Hsc70, were very similar in all 
our assays, but we chose Hsp72 since it appears to be most important in tau biology (see 
Chapter 1 and [28]). Finally, we decided to include BAG2. The reasoning behind this last 
choice is that BAG2 is expressed in neuronal systems and it forms a tight complex with 
Hsp72 (as discussed above). Thus, although it doesn’t directly contribute to ATP 
turnover, we wanted to provide a more “physiological” target. In other words, any 
compounds that bind to the BAG2-Hsp72 interface would need to compete with this 
contact in vivo, so we wanted to model this environment in the HTS campaign.  
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The primary HTS screen was performed with the ChemBridge 100K library, which is a 
structurally diverse chemical collection of drug-like molecules. The assay was carried out 
as described in Chapter 2. The protein concentrations were Hsp72 (0.5 µM), DJA2 (0.1 
µM) BAG2 (0.25 µM) and ATP (1 mM). Test compounds were included at final 
concentrations of 40 µM. The positive control was all of the components except the 
Hsp72. The negative control was DMSO. From this screen, active compounds were 
selected based on two criteria: (a) samples that either increased or decreased the 
phosphate production by 30% or (b) samples that had signals more than 3 standard 
deviations (3SD) from the negative controls. Using these criteria, we identified 1312 
inhibitors and 470 activators. To confirm these activities, hits were subjected to a 
confirmation screen in duplicate using the original library compound. This process 
reduced the inhibitors to 973/1312 and activators to 202/470. Next, because the assay was 
fluorescence-based, we tested the intrinsic fluorescence of the inhibitors and activators 
and removed any that had values greater than 110% of DMSO control.  This filter 
reduced the actives to: 471/1312 inhibitors and 74/470 activators. The top 91 inhibitors 
and 29 activators were then selected for dose response curves (eight concentrations 
between 0 and 100 µM). From this analysis, we repurchased 18 compounds (8 activators 
and 10 inhibitors) based on their potency and the synthetic tractability of the scaffold. 
These re-purchased compounds were then retested in ATPase assays (activators -
Appendix 3.4, inhibitors - Appendix 3.5). We were pleased to find that 5 of these 
compounds (all inhibitors) retained activity (Figure 3.8), which is a typical confirmation 
rate upon retesting of fresh compound (CCG, personnel communication). 
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Characterization of these inhibitors to identify their mechanism-of-inhibition and their 
binding sites is currently ongoing in the Gestwicki laboratory. 
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3.2.7 Hits compounds exhibit selectivity against different chaperone complexes 
As mentioned in Chapter 1, 
the human Hsp70 system is 
highly similar to the 
prokaryotic system. For 
example, DnaK is more than 
50% identical and 75% similar 
to human Hsp72. Thus, we 
wanted to ascertain whether 
the five inhibitors identified 
above would retain activity 
against the prokaryotic DnaK-
DnaJ-GrpE system. We were 
pleased to find that these 
compounds were also inhibitors of this system, although the IC50 values were not 
identical (Figure 3.9 and Table 3.2). More work is needed to understand the mechanisms 
and potential selectivity of these compounds, but this finding provides further support for 
the potential of this screening method and the potential of these active compounds. 
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3.3 Discussion 
The major goals of the work in this Chapter were to characterize human Hsp70 chaperone 
systems using biochemical methods and use this information to implement a HTS 
experiment. These studies are inspired by the efforts in Chapter 2, in which we describe 
the concept of “gray box” screening, which is a new method designed to identify 
inhibitors of protein-protein interactions. The major challenge of this approach is that the 
multi-protein complex must be reconstituted and, thus, the biochemical activity of the co-
factors must be defined. Towards that goal for the human Hsp70 system, we 
characterized the effects of co-chaperones on ATPase and luciferase refolding activity. 
During this process, we made a number of unanticipated findings that suggest substantial 
differences between the human and prokaryotic systems. For example, we found that 
human Hsp70s bind to model substrate with only a 4-fold weaker affinity, yet this 
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interaction does not stimulate ATPase activity. This result is in stark contrast to what is 
found in DnaK [29, 30]. These results suggest that there are substantial differences in the 
allostery in the human and prokaryotic systems. Recent findings from the Mokranjac 
group have provided some further support of this idea. Using a FRET assay, they found 
that DnaK is less flexible than human mitochondrial Hsp70 [31]. Thus, despite the high 
homology between these proteins at the sequence and structural level, there might be 
considerable differences in more subtle regulatory aspects, such as allostery and 
dynamics. 
 
Another surprising finding is that different J proteins have different apparent affinities for 
Hsp70s. Specifically, we found that Hsj1 has a weaker potency than DJA1 and DJA2. 
This seems to occur despite the near identity of the conserved J domains (~88%), 
suggesting that regions outside of the J domain may be responsible for the differences. In 
fact, the G/F rich domain of DnaJ has been found to contribute to ATPase stimulation 
[10, 32] and this region is less conserved in DJA1, DJA2 and Hsj1 (~55%), providing a 
possible mechanism. Moreover, despite the ability of these J proteins to stimulate ATP 
turnover, only DJA2 was able to support refolding. Dogma in the chaperone field has 
suggested that ATP stimulation is required for luciferase folding, yet these results clearly 
demonstrate that these two activities are not directly linked. Work by other members of 
the Gestwicki group (using point mutants) has also supported this model [33]. 
 
Finally, we found that the human BAG proteins fail to stimulate steady state ATP 
turnover. Although this finding does not preclude the idea that BAG proteins might 
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stimulate in single turnover assays, they clearly show that human BAGs have a different 
function than prokaryotic GrpE in the ATPase cycle.  This difference was not due to a 
failure to bind Hsp70, because we used flow cytometry and ITC to confirm this protein-
protein interaction and found values similar to those reported in the literature [34]. We 
are currently pursuing structures of Hsp72 bound to BAG2 to help us understand these 
differences. Together, these findings have highlighted important and unexpected 
differences between the prokaryotic and human Hsp70 systems. 
 
In the final part of this Chapter, we successfully carried out a HTS experiment using the 
Hsp72-BAG2-DJA2 complex as the target and identified small molecules that modulate 
the human chaperone system. These findings provide good support of our “gray box” 
screening concept. Moreover, these results have provided approximately 5 new chemical 
scaffolds with potential to be used as novel Hsp70 modulators. These chemical probes 
may be new tools for tuning the protein-protein interactions in the Hsp70 chaperone 
complexes.  
 
Notes 
Srikanth Patury and Jason Gestwicki designed the experiments. Tomoko Komiyama and 
Amanda Lewis helped with the protein purification and HTS experiments. Tomoko 
Komiyama, Robert Briski, Bryan Dunyak performed follow-up studies on the hit 
compounds. Jennifer Rauch aided in the BAG expression and binding assays. Tom 
McQuade and Steve Vander Roest helped run the chemical screen in the CCG. 
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3.4 Experimental Procedures 
 
3.4.1 Protein purification 
Hsp72, Hsc70, DJA2, BAG2, BAG3 were cloned into the pMCSG7 plasmid (Midwest 
Center for Structural Genomics, Bethesda, MD) by ligation independent cloning. For 
Hsp72, Hsc70 expressiont, 25 mL of overnight (37 C) LB culture of Rosetta (DE3) 
culture was poured into 1 L of Terrific Broth. After 3 hours incubation at 37 C, the 
culture was cooled down to 28 
o
C for 2 hours before overnight induction of expression 
with 200 µM IPTG overnight, and the cell pellet was stored at -80 C until use. For 
DJA2, BAG2, BAG3, a single colony of Rosetta (DE3) culture was inoculated into 5 mL 
LB. After 6 hours of incubation at 37 C, the 5 mL starter culture was poured into 1 L 
Terrific Broth and the larger culture was incubated at 37 C until OD600 reached 0.4 - 0.6. 
Expression was induced by 500 µM IPTG under 18 C for ~15 hours with shaking and 
the cell pellet was stored in -80 C until use. All proteins were purified by standard Ni 
purification protocol using Ni-NTA His•Bind® Resin (Novagen, Darmstadt, Germany) 
as following. The cell pellet was resuspended in His-binding buffer (25 mM Tris, 600 
mM KCl, 5 mM imidazole, pH 8.5) supplement with protease inhibitor cocktail (1 tablet 
per liter of original culture) and the bacterial cells were lysed by sonication (3.5 minutes, 
30 sec on/off cycle, 63%). The cell debris was removed by centrifugation at 20,000 rpm 
for 45 mins. The supernatant was incubated with Ni-NTA resin for 2 hours at 4 C. To 
remove the contaminated ATPase activity in the J-protein and NEF samples, the His-
proein-bound Ni-NTA resin was washed extensively by 100 mL of His-binding buffer, 
150 mL 25 mM Tris buffer (40 mM Imidazole, 300 mM KCl, 3% ethanol, pH 8.0), and 
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finally with 500 mL 25 mM Tris buffer (30 mM imidazole, 100 mM KCl, 3% ethanol, 
pH 8.0). The proteins were eluted by His-elution buffer (50 mM Tris, 300 mM Imidazole, 
150 mM KCl, pH = 8.0) and the J-proteins were concentrated, exchanged into 25 mM 
HEPES buffer (150 mM KCl, 5 mM MgCl2, pH 7.5) and stored at -80 C until use. For 
the BAG proteins an additional purification step included the MonoQ column. 
 
3.4.2 ATPase Assays  
We followed the ATPase assay protocol developed by Lyra Chang, a graduate student in 
the lab[29]. Briefly, samples were prepared with the addition of Hsp70, Hsp40, NEFs to a 
total volume of 15 μl in each well. Next, 10 μl of 2.5 mM ATP was added to start the 
reaction. The final concentrations were: ATP (1 mM), Hsp70 (0.5 μM) unless otherwise 
noted. Intrinsic ATPase rate was measured with Hsp70 (0.6 μM) in the absence of co-
chaperones or substrate. The final concentrations of Hsp70, Hsp40, NEF are reported for 
each experiment in the results section. For steady state conditions, samples were 
incubated at 37 C for three hours, then 80 μl of malachite green reagent was added to 
each well, immediately followed by 10 μl of 32% (w/v) sodium citrate. Samples were 
mixed thoroughly and incubated at 37
 C for 15 minutes. Finally, OD620 was measured. 
All experiments were preformed in triplicate and the signal from non-specific ATP 
hydrolysis in controls lacking Hsp70 was subtracted. A phosphate standard curve (using 
potassium dibasic phosphate) was generated each day and used to convert the units to 
pmol Pi/μg DnaK/min.  
Stimulation curves were evaluated by fitting the data using a hyperbolic fit with a non-
zero intercept; 
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y = Vmax* x ∕ (Km + x) + b 
The non-linear fit was performed using GraphPad Prism version 4.0 for Windows 
(GraphPad Software San Diego, CA).  The protocol for the HTS ATPase assay was taken 
from the work published by Yoshi Miyata, a graduate student in the Gestwicki lab[35]. 
 
3.4.3 Luciferase Refolding Assays 
The luciferase refolding activity of DnaK WT and mutants were evaluated as described 
with minor changes (ref). Briefly, denatured firefly luciferase was prepared by beginning 
with a concentrated stock (8.2 μM) of luciferase with 6 M GuHCl in 25 mM HEPES 
buffer (50 mM potassium acetate, 5 mM DTT, pH 7.2). This stock was incubated at room 
temperature for one hour and then diluted to 0.2 μM with the same HEPES buffer without 
GuHCl. This preparation was used as the stock solution for final sample preparation. 
Enzyme mix (10 µl) containing Hsp70, Hsp40, NEF, denatured firefly luciferase in 39 
mM HEPES (170 mM potassium acetate, 1.7 mM magnesium acetate, 3 mM DTT, 12 
mM creatine phosphate, 50 U/ml creatine kinase, pH 7.6) was first added into each well 
of 96-well white plate and then 4 l of 3.5 mM ATP, dissolved in water, was added to 
start the reaction. The final concentration of Hsp70 was 1 μM, denatured luciferase was 8 
nM, and ATP was 1 mM unless otherwise noted. The concentration of Hsp40 and NEF 
are reported for each experiment in the results section. After one hour of incubation at 37 
C, equilibrium was reached and 14 μl of 0.5% or 2% (v/v) SteadyGlo reagent in 50 mM 
glycine buffer (30 mM MgSO4, 10 mM ATP and 4 mM DTT, pH 7.8) was added into 
each well, and the luminescence was measured. For each experiment, the signal from a 
negative control containing everything but Hsp70 was subtracted. The rate of refolding 
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was obtained by converting the luminescence unit into luciferase concentration using 
standard curve, and analyzing by linear regression fit using GraphPad Prism 4.0 (for 
Windows). 
 
3.4.4 Holdase Activity Assays 
Native luciferase was diluted to 0.032 μM in 50 mM HEPES (10 mM MgSO4, 300 mM 
KCl, 20 mM DTT, pH 7.5) and loaded into a 96-well PCR plate (Thermofisher) (5 
μl/well). Next, 5 μl of 2 μM Hsp70 was added in triplicate into the wells containing 
luciferase. The reaction mixtures were heated to 39.5 C for 8 minutes and the samples 
were transferred into a 96-well, opaque, white microtiter plate (Thermofisher). Next, 10 
μl of 0.5 % v/v SteadyGlo reagent, as described in the previous section, was added to 
each well and the luminescence was measured. 
 
3.4.5 Octet Red Binding Assays 
Octet RED platform binding experiments were conducted at 25ºC using 
Streptavidin coated biosensors (SA sensors, ForteBio, Cat no 18-0019) on the Octet 
RED biosensor platform (ForteBio) in 25mM HEPES, 5mM MgCl2, 10mM KCl, 0.3% 
Tween-20, 1mM ATP pH 7.5. Sensor tips were pre-wet for 15 min in buffer immediately 
prior to use, and the 96 well micro-plates were filled with 200μl of sample or buffer per 
well and agitated at 1000rpm. Biotinylated DnaK and Hsp72 (0.1mg/ml) were 
immobilized on SA sensors to saturation for 20 min (typical loading levels 2.5nm). 
Binding interaction of NRLLLTG was monitored over a range of concentrations 
(association phase for 5 min, dissociation phase for 5 min). Data was analyzed using both 
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kinetic (1:1 binding, global fit) and steady state analysis and the binding constants were 
indistinguishable. Reference sensors were used to correct for background and baseline 
drift. Experiments were done in duplicate. 
 
3.4.6 Flow Cytometry-based binding assays 
Biotinylated Hsp72 was attached to polysterene streptavidin coated beads (Spherotech) 
and mixed with increasing concentrations of Alexa Fluor 488 labeled Bag protein in 
buffer A (25mM HEPES, 5mM MgCl2, 10mM KCl, 0.3% Tween-20 pH 7.5). Binding 
was detected by measuring bead-associated fluorescence using an Accuri C6 Flow 
Cytometer. Competition experiments were performed in a similar manner with 
fluorophore labeled Bag protein (30nM) and titrating in either unlabeled Hsp72 or Bag. 
Beads capped with biocytin were used as a negative control for each experiment.  
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3.5 Appendices 
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Chapter 4 
 
 
Biophysical characterization of the Hsp70-CHIP chaperone complex 
 
 
 
4.1 Abstract 
One of the major goals of this thesis work is to characterize the biochemical properties of 
multi-protein chaperone complexes. As described in Chapters 2 and 3, these insights have 
permitted the discovery of new chemical inhibitors via “gray box” screening. In this 
Chapter, we focus on understanding the interaction between human Hsp70 and 
tetratricopeptide (TPR) domain co-chaperones, one of the least well-described co-
chaperone interactions.  As discussed in Chapter 1, the Hsp70/Hsp90 molecular 
chaperone machinery plays a central role in protein quality control in the cell by assisting 
in the folding and/or degradation of protein substrates. Folding is coupled to cycles of 
ATP hydrolysis and is regulated by a cohort of Hsp70- and Hsp90-bound co-chaperones. 
However, not every attempt to fold is successful, and the chaperone machinery can also 
direct misfolded proteins to the degradation pathways, including the ubiquitin-dependent 
proteasome system (UPS). A complex between Hsp70 and the E3 ubiquitin ligase CHIP 
(carboxyl terminus of Hsc70-interacting protein) appears to be particularly important in 
promoting the UPS-mediated degradation of a number of substrates. Based on pull-down 
assays, CHIP appears to bind to both Hsp70 and Hsp90 through its tetratricopeptide 
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(TPR) domain, but less is known about the affinity of this interaction and whether other 
regions of the proteins might contribute. To better understand this process, we have 
measured the affinity of CHIP binding and to the chaperones and mapped the key 
domains using truncation. These studies confirmed that much of the free energy of 
binding originates with CHIP’s TPR domain binding to the C termini of Hsp70 and 
Hsp90, but additional contacts in the substrate-binding domain (SBD) of Hsp70 also 
make significant contributions. We also found that none of these CHIP-Hsp70 
interactions impacted the steady state ATP turnover rate of Hsp70. Finally, we used in 
vitro ubiquitination assays to demonstrate that the TPR and U-box domains of CHIP are 
necessary for chaperone ubiquitination. Together, these studies suggest that interaction 
between the TPR domain of CHIP with molecular chaperones, while not sufficient to 
fully describe the affinity, is critically important in facilitation substrate ubiquitiylation, 
possibly by fine-tuning the relative position of substrate and CHIP in the Hsp70 complex. 
Together, these results are expected to significantly assist efforts to discover and develop 
small molecules that inhibit the Hsp70-CHIP complex.  
 
4.1.1 Hsp70 and Hsp90 chaperones triage misfolded proteins 
As discussed in Chapter 1, the major chaperones Hsp70 and Hsp90 act together to 
regulate the function, trafficking and turnover of multiple protein substrates [1] Both 
chaperones bind client proteins in an ATP-dependent manner and their activities are 
regulated by a variety of co-chaperones [2, 3] When the Hsp70/Hps90 chaperones 
encounter a misfolded protein, they are thought to first attempt to rescue the protein via 
the refolding pathway and , at the same time, sequester the misfolded species to prevent 
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toxic interactions[4]. However, Hsp70 and Hsp90 have also been linked to the 
degradation of substrates via the proteasome and autophagy pathways [5]. Comparatively 
less is known about the mechanisms of chaperone-assisted degradation. 
 
4.1.2 CHIP links chaperones to the ubiquitin-dependent degradation pathway 
Proteins destined for degradation by the ubiquitin-dependent proteasome system (UPS) 
are labeled with a polyubiquitin chain and sent to the 26S proteasome [6]. Briefly, 
ubiquitylation of substrates is mediated by a series of three factors, namely activating 
(E1), conjugating (E2) and ligase (E3) enzymes [7]. There is considerable evidence that 
Hsp70/Hsp90 chaperones promote degradation of substrates such as glucocorticoid 
receptors (GR)[8] and cystic fibrosis transmembrane conductance regulator (CFTR) [9] 
by directly recruiting E3 ligases. The two E3 ligases known to interact with Hsp70/Hsp90 
are Parkin and CHIP [10, 11]. CHIP appears to be particularly important and it is a 35 k-
Da protein that was first identified in a yeast two hybrid screen for proteins containing 
tetratricopeptide (TPR) domains [12].  For some proteins, such as the GR, CHIP appears 
to be the sole dedicated E3 responsible for turnover, whereas other substrates, such as 
neuronal nitric oxide synthase (nNOS), can be degraded by multiple E3 ligases [13]. 
CHIP doesn’t appear to act by itself but, rather, its activity is Hsp70- and Hsp90-
dependent [14, 15]. CHIP binds to both Hsp70 and Hsp90 at their C-terminal ‘EEVD’ 
motifs and this interaction seems to require CHIP’s TPR domain [12, 16]. In turn, CHIP 
binds to the UbcH5 family of E2-conjugating enzymes through a carboxyl terminal U-
box domain[17]. Through formation of this multi-protein complex, CHIP has been shown 
to ubiquitinate Hsp70/Hsp90 substrates, diverting them to the proteasome [18].   
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4.1.3 To fold or to degrade: TPR co-chaperones determine function 
In addition to CHIP, the TPR domain is a chaperone-binding motif found in several co-
chaperones. The TPR domain is characterized by a tandem arrangement of three 34 
amino acid motif that forms an antiparallel -helical hairpin. Most proteins that have 
TPR domains also have additional domains with other activities and, thus, these co-
chaperones are thought to recruit unique capabilities to the Hsp70 complex. For example, 
HOP has three domains (TPR1, TPR2A, and TPR2B) with three TPR motifs each [19]. 
HOP preferably binds to the ADP-bound form of Hsp70 via TPR1 and TPR2B, while 
TPR2A specifically binds to Hsp90 [20]. In this way, Hop bridges Hsp70 and Hsp90, 
assists substrate transfer between these chaperones and is believed to promote substrate 
folding. Thus, although both HOP and CHIP bind via TPR domains, the outcomes of 
these interactions are diametrically opposed: HOP favors folding, while CHIP favors 
degradation. Based on these observations and many others, it is thought that competition 
between TPR co-chaperones might drive combinatorial assembly of chaperone 
complexes with specific functions.  
 
4.1.4 The molecular mechanism of the Hsp70/Hsp90/CHIP triage decisions is not 
known 
Despite the importance of the TPR-chaperone interaction, surprisingly little is known 
about the biochemistry of these protein complexes. Most of what is known comes from 
overexpression and pulldown experiments, such as glutathione-S-transferase (GST) 
fusion protein assays [12, 18, 21]. Based on these studies, the TPR domain and an 
adjacent charged region of CHIP appear to be necessary for its interaction with Hsp70, 
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while the carboxy terminal domain (CTD) of Hsc70, including the EEVD motif, are 
required on the other side [18]. However, biochemical studies on the Hop-Hsp70 
interaction suggest that binding between Hsp70 and Hop is not solely dependent on TPR-
EEVD interactions [19]. Further, a recent structure of the Hsp70-Hop-Hsp90 complex 
also suggested the potential importance of contacts outside the EEVD [22].  Thus, our 
hypothesis is that the CHIP interactions with Hsp70/Hsp90 may involve important, and 
previously under-studied, contacts outside the EEVD-TPR contact. To clarify these 
important questions, our goal was to biophysically characterize the binding determinants 
between CHIP and Hsp70.  
 
4.2 Results 
 
4.2.1 Design of CHIP and Hsp70 truncations 
Qualitative “domain mapping” analysis between CHIP and Hsp70 that has been 
performed by Ballinger et al [12], in which they generated a series of truncations in both 
CHIP and Hsp70 (Figure 4.1). Accordingly, we designed a similar set of constructs 
including, a TPR domain deletion (ΔTPR) and two C-terminal truncations 1-142 and 1-
197 (CHIP-142 and CHIP-197, respectively). We also deleted the first 25 amino acids, 
which have been shown to be important in auto-ubiquitylation of CHIP (CHIP Δ25). On 
the Hsp70 side of the protein-protein contact, we deleted the EEVD motif (Hsp70-
ΔEEVD) and also used the prokaryotic Hsp70, which naturally lacks the EEVD. Next, 
we also made a truncation (Hsp70-555) in which the entire C-terminal “lid” domain 
(CTD) is deleted. Finally, the nucleotide binding domain (NBD) of Hsp70 has been 
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shown to be dispensable for binding to CHIP, so we also generated this construct (Hsp70-
NBD). 
 4.2.2 Development of a Surface Plasmon Resonance (SPR) binding assay to measure 
the CHIP-Hsp70 binding affinities 
To measure the binding affinities, we developed an assay using Surface Plasmon 
Resonance 
(SPR). This 
platform 
employed a 
streptavidin 
(SA) 
Biacore chip 
in which we 
immobilized 
biotinylated 
Hsp70 or 
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the various truncations. For each protein, we were able to achieve immobilization 
densities of ~1000 response units (RUs). We then evaluated the binding of recombinant 
CHIP (and truncations) by injecting several different concentrations (ranging from 0 to 
500 nM) at a flow rate of 20 µL/min. Binding was determined by subtracting the signal 
from a control lane in which DnaK was immobilized (although binding to this lane was 
insignificant). Binding affinities were then determined using both kinetic and 
thermodynamic analyses yielding an 
apparent KD of 190 ± 3.6 nM (Figure 
4.2). To confirm that binding was 
specific, we verified that free Hsp70 
competes with CHIP binding to the 
surface. This experiment provided an 
IC50 of 716 ± 90 nM at two different 
constant concentrations of CHIP 
(100 nM and 250 nM), suggesting 
that the interaction is specific.  
 
Using this SPR binding assay, next we measured the binding affinities of the different 
truncations (Table 4.1). In general, our quantitative findings agreed with the previous 
qualitative domain mapping analysis [12]. For example, the TPR domain of CHIP 
appeared to be important for the interaction, because deleting it resulted in a 3-fold loss in 
affinity. The coiled-coil domain between residues (142-197) of CHIP also appeared to 
contribute (Table 4.1). This is an interesting result because this domain is not conserved 
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in other TPR proteins. Thus, it may contribute to specificity in binding CHIP to Hsp70. 
When we examined the Hsp70 truncations, we found that domains in Hsp70 other than 
the EEVD region also contribute to the binding interactions. Specifically, we found that 
deletion of the EEVD region resulted in only a loss of 2-fold in affinity (Table 4.1). 
Moreover, the Hsp70-555 construct was still able to weakly bind to CHIP, indicating that 
residues in the substrate-binding domain (SBD) also participate. Together, these finding 
greatly enhance our knowledge of the contacts between Hsp70 and CHIP. 
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4.2.3 CHIP does not display nucleotide dependence in binding to Hsp70 
Since nucleotide binding and hydrolysis result in conformational changes in Hsp70, we 
wanted to measure the binding affinities for CHIP under different nucleotide states. 
Nucleotide dependence has 
already been shown for other TPR 
domain containing proteins, such 
as Hop, which binds Hsp70-ADP 
2-fold better than Hsp70-ATP 
[20]. However, in our SPR studies 
we found that CHIP did not have a 
preference for Hsp70’s nucleotide 
state. Both affinities were 
determined to be approximately 240 ± 13 nM. The functional significance of this finding 
is not yet clear, but work in the Gestwikci laboratory by another graduate student is 
exploring this issue. 
 
4.2.4 CHIP binds to Hsp90 with slightly weaker affinity 
CHIP has been shown to bind both Hsp90 and Hsp70, guiding triage decisions in protein 
quality control [18]. Traditionally, Hsp90 bound complexes are associated with pro-
folding activity, while Hsp70 bound substrates are more prone to degradation. Thus, we 
wanted to measure if there was any difference in the binding affinities between CHIP and 
Hsp70/Hsp90. Briefly we immobilized biotinylated Hsp90 (1950 RUs) on the SA Biacore 
chip surface and then injected CHIP at a flow rate 20 µL/min. 
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In this platform, we found that CHIP bound Hsp90 with only a mildly weaker affinity (Kd 
= 380 ± 29 nM). Thus, CHIP binds both Hsp70 and Hsp90 with similar affinity. Again, 
the functional significance of this finding isn’t yet clear, but it does suggest that other 
factors besides the binary protein-protein interaction affinity contribute to the ability of 
the Hsp70-CHIP complex to more strongly favor degradation. 
 
4.2.5 FRET assays confirm binding between Hsp70/CHIP 
Because any affinity measurement platform can be prone to artifacts, we wanted to 
develop a secondary assay to confirm the binding interactions. Specifically, we wanted to 
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use a solution phase, homogeneous platform to complement the surface-based SPR 
technique. Towards that goal, we used a Forster Energy Resonance Transfer (FRET)-type 
assay (Figure 4.6A). Briefly, Hsp70 was labeled with the fluorescent donor 
AlexaFluor488 (AF-488), which has an emission wavelength of 525 nm. Then,  CHIP 
was labeled with Black Hole Quencher10 (BHQ-10), a strong FRET acceptor that 
absorbs at 507 nm. This system allows sensitive measurement of binding by an apparent 
quench in AlexaFluor488 fluorescence. Labeling of the two partners via lysine residues 
proceeded smoothly, with average incorporations of ~ 2-3 per protein. As predicted from 
the SPR studies, we observed a dose-dependent quench with increasing concentrations of 
labeled CHIP (Figure 4.6B). Interestingly, the observed affinity was stronger than that 
predicted by SPR (Kd – 55 ± 5.2 nM), suggesting that the surface may partially inhibit 
binding or that the labeling reactions strengthened the apparent affinity. 
 
Next, we measured the ability of the various truncations to compete with the Hsp70-
CHIP interaction. Briefly we incubated a constant concentration of AF-488 labeled 
Hsp70 (50 nM) and BHQ-10 labeled CHIP (50 nM) with unlabeled mutants for 1 hour 
and then monitored quenching. The relative results matched well with our SPR data, in 
that the TPR domain was found to be important for binding (Figure 4.6C). The CHIP-197 
truncation was also able to compete, again showing that the coiled-coil domain 
contributes to the interaction. Similarly the Hsp70 truncations were also able to compete 
with the interaction (Figure 4.6D), consistent with the SPR results. Interestingly, 
synthetic EEVD peptide was not able to compete this interaction (data not shown), 
further suggesting that the EEVD-TPR contact, while a contributor to the interaction, is 
132 
not sufficient to describe the entire affinity. 
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4.2.6 FRET assay to monitor Hsp90-CHIP binding shows similar results to SPR 
We also wanted to confirm the Hsp90 binding affinities to CHIP in the FRET assay. This 
experiment was particularly important because a recent publication [23] reported that 
Hsp90 binds with a stronger affinity to CHIP than Hsp70. However, that study used 
ubiquitination assays, so we wanted to additionally measure the direct binding affinity. In 
this assay, similar to what we found with SPR, Hsp90 bound with a slightly weaker 
affinity than Hsp70 (81 ± 4.4nM) (Figure 4.7A), Next, we performed the binding of the 
truncations, which revealed that the required domains for binding of CHIP and Hsp90 
parallel those needed for Hsp70 interactions. Specifically, the TPR domain is most 
important, with come contribution by the charged region (Figure 4.7B). 
 
 
4.2.7 TPR domain is required for the ubiquitination of Hsp70 
CHIP ubiquitinates Hsp70 in cells and this activity promote turnover of the 
chaperone[24]. Based on our biochemical studies, we wanted to assess which domains 
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were necessary for this functional 
activity of CHIP. Thus, we collaborated 
with the Paulson laboratory (Dept. of 
Neurology) to establish in vitro 
ubiquitination assays. Briefly CHIP and 
Hsp70 were incubated with a mixture of 
components required for the in vitro 
reconstitution of the ubiquitin cycle [6]: 
ubiquitin (Ub), E1 and E2 enzymes and 
ATP. CHIP_mediated conjugation of ubiquitin to Hsp70 was then measured (Figure 4.8). 
Using the series of CHIP truncations, we found that the TPR domain is absolutely 
required for the functional activity of CHIP. In addition, the truncations CHIP-142, 
CHIP-197 and CHIP Δ25 all lacked activity. Thus, multiple regions of CHIP are required 
for functional activity in the Hsp70-CHIP complex. 
 
4.3 Discussion 
 
4.3.1 The TPR domain in CHIP and the EEVD motif in Hsp70 play important roles 
in binding but other regions also contribute 
CHIP along with chaperones Hsp70 and Hsp90, plays a central role in the triage 
decisions [3]. In this Chapter, we sought to characterize, for the first time, the affinities 
between CHIP and the chaperones to determine which motifs contributed to binding. 
Using SPR and a FRET assay, we found that the TPR domain in CHIP is important for 
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binding to both Hsp70 and Hsp70, with the coiled-coil region also playing a role. On the 
other side, the EEVD motif of Hsp70 was also found to be involved in binding, but not 
required: the Hsp70-ΔEEVD truncation had only a 2-fold weaker affinity for CHIP. 
Further, the Hsp70-555 truncation retained some binding affinity, suggesting that regions 
in the carboxy terminal domain (CTD), interact with CHIP. This result parallels studies 
on the Hop-Hsp70 interaction [25]. 
 
4.3.2 Nucleotide state does not influence CHIP binding to Hsp70 
Hop has been shown to preferentially bind Hsp70 in an ADP bound state [20]. Thus, we 
wanted to explore whether CHIP also shared this discriminatory ability. Unexpectedly, 
we found that the affinity of CHIP-HSp70 binding was nucleotide independent. Thus, we 
propose that the HOP-Hsp70 contact surface may be more extensive than the Hsp70-
CHIP surface, allowing communication of the nucleotide-specific conformation between 
Hop and Hsp70, but not CHIP and Hsp70. More work is required to understand this 
difference and learn its potential functional significance in protein quality control. 
 
4.3.3 Implications of this work on the development of small molecule inhibitors 
A major theme of this thesis is that careful, biochemical and biophysical characterization 
of chaperone complexes can be important in the subsequent discovery of new chemical 
inhibitors, especially using “gray box” screening. Thus, a goal of this Chapter was to 
better understand and measure the binding of CHIP to Hsp70 and Hsp90, to enable 
potential chemical studies. Recently, Chris Evans and Matt Smith in the Gestwicki 
laboratory identified a class of natural products, based on spergualin, that inhibit the 
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Hsp70-CHIP interaction [26] (and unpublished work). Satisfyingly, the biophysical 
characterization of the Hsp70-CHIP interaction described in this Chapter has been useful 
in the rational synthesis of more potent and selective spergualin derivatives. I expect that 
future efforts will continue to identify novel inhibitors of TPR interactions that can be 
used to both (a) better understand the chaperone-TPR interactions and (b) probe the 
importance of this interaction in cellular and animal models of disease. 
 
Notes: 
Srikanth Patury and Jason Gestwicki designed the experiments. The ubiquitylation assays 
were performed by Matthew Scaglione and the FRET studies were performed, in part, by 
Matthew Smith. Andrea Thompson helped with SPR studies. Matthew Scaglione and 
Srikanth Patury made the CHIP and Hsp70 truncations. Srikanth Patury performed the 
bulk of the SPR studies, some FRET studies and the analyses.  
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4.4 Experimental Procedures 
 
4.4.1 Protein purification 
All Hsp70 truncations were cloned into the pMCSG7 plasmid (Midwest Center for 
Structural Genomics, Bethesda, MD) by ligation independent cloning and transformed 
into Rosetta (DE3) cells for expression, as previously described in Chapter 3. To express 
Hsp70 truncations, 25 mL of overnight (37 C) LB culture of Rosetta (DE3) culture was 
poured into 1 L of Terrific Broth. After 3 hours incubation at 37 C, the culture was 
cooled down to 28 
o
C for 2 hours before overnight induction of expression with 200 µM 
IPTG overnight, and the cell pellet was stored at -80 C until use. The WT and Hsp70 
truncations were purified using same procedures as described except the addition of the 
EDTA-free protease inhibitor cocktail (Roche) (1/4 tablet for each sample) in the lysis 
buffer and the omitting of final Ni-NTA resin clean-up step for Hsp70 truncations.  All 
CHIP truncations were expressed in E. coli (BL21 DE3 LysS) and purified on glutathione 
sepharose resin (GE Healthcare)[27, 28]. All GST tagged proteins were cleaved with 
precission protease and purified prior to use. UbcH5c was purified as previously 
described [29]. 
 
4.4.2 Surface Plasmon Resonance experiments 
A streptavidin(SA) chip (GE Healthcare) was docked and equilibrated with HBS buffer 
(10 mM HEPES, 150 mM NaCl, pH 7.4 containing 0.005% Tween-20) overnight at 5 
uL/min. All experiments were performed at 25 °C. Proteins were biotinylated using 
Sulpho-NHS-LC-Biotin (Invitrogen, catalog B-6353) following the protocol provided by 
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Invitrogen(MP00143). Hsp70’s were immobilized in MES buffer (20mM MES, 150 mM 
NaCl, pH 5.5, 0.01% Tween-20). Average immobilization responses for the various 
Hsp70 truncations were approximately 1200 RUs. After immobilization of all 
biotinylated proteins, the chip was equilibrated for at least 4 hours at 5 µL/min. Varying 
concentrations of CHIP and its truncations(10 nM – 2 µM) were prepared in HBS buffer 
and 40 µL were injected at 20 µL/min. For competition experiments, CHIP (100nM) and 
unlabeled Hsp70 (50 nM – 10 µM) were combined in HBS immediately prior to 
injection. For both direct and competition binding, the binding surface was regenerated 
with Regen buffer (HBS buffer, 100mM NaOH, 100mM MgCl2) with a pulse injection of 
20 µl until the baseline response was reached. Data was fit thermodynamically by using 
the change in RU value 5 seconds prior to the end of the association phase. The 
concentration dependent change in immobilization was then fit by non-linear regression 
analysis using GraphPad Prism software, from which Kd or Ki values were determined. 
 
4.4.3 FRET assays 
Protein samples were labeled and prepared as previously described[30]. Briefly, amine 
reactive Alex488 (Invitrogen) was used to label Hsp70 and Hsp90 by mixing the dye and 
protein at a 10:1 molar ratio in bicarbonate buffer (100mM NaHCO3 [pH 8] containing 
150mM NaCl). CHIP was similarly labeled using BHQ-10 (Biosearch Technologies) at a 
molar ratio of 50:1, dye: protein. Excess labels were removed by passage through Zeba 
desalting columns (Thermo Scientific) equilibrated with hepes-buffered saline. Using the 
extinction coefficients supplied by the manufacturer, label concentrations were 
determined for each protein sample and used to calculate the amount of molar 
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incorporation. MIR values for Hsp70, Hsp90, and CHIP were 3.2, 2.4, and 14.1 
respectively. All quenching assays were performed at the indicated protein concentrations 
in 10mM Hepes buffer (ph 7.4) containing 150mM NaCl, and 0.05% Tween-20. 
Equilibrium binding measurements were taken in a 384-well microplate format using a 
SpectraMax M5 microplate reader (Molecular Devices). Each sample was excited at 
480nm and total fluorescence was read at 525nm with a 515nm cut-off. The average 
fluorescence intensity of 15 reads was recorded for each sample. 
 
4.4.4 Ubiquitination assays 
Ubiquitination was typically performed for 1 hr at 37°C in 10 μl mixtures containing 
buffer A (50 mM Tris pH7.5, 50 mM KCl, 0.2 mM DTT), Ubmix (2.5 mM ATP, 5 mM 
MgCl2, 50 nM Ube1 (E1 enzyme), and 100 µM ubiquitin), 1 µM indicated E2, 1 µM 
CHIP, prepared as previously described [31]. Reactions were stopped by addition of 
SDS-Laemmli buffer and boiling, followed by separation of proteins by SDSPAGE and 
visualization by Western blotting with appropriate antibodies. Mouse mono-clonal 
antibody to Hsp70 (Assay Designs) was used to visualize ubiquitin transfer. 
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141 
 
 
D
D
142 
4.6 References 
1. Pratt, W.B. and D.O. Toft, Regulation of signaling protein function and 
trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 
(Maywood), 2003. 228(2): p. 111-33. 
2. Hartl, F.U., Molecular chaperones in cellular protein folding. Nature, 1996. 
381(6583): p. 571-9. 
3. Picard, D., Heat-shock protein 90, a chaperone for folding and regulation. Cell 
Mol Life Sci, 2002. 59(10): p. 1640-8. 
4. Frydman, J., Folding of newly translated proteins in vivo: the role of molecular 
chaperones. Annu Rev Biochem, 2001. 70: p. 603-47. 
5. Pickart, C.M. and M.J. Eddins, Ubiquitin: structures, functions, mechanisms. 
Biochim Biophys Acta, 2004. 1695(1-3): p. 55-72. 
6. Hershko, A. and A. Ciechanover, The ubiquitin system. Annu Rev Biochem, 
1998. 67: p. 425-79. 
7. Cyr, D.M., J. Hohfeld, and C. Patterson, Protein quality control: U-box-
containing E3 ubiquitin ligases join the fold. Trends Biochem Sci, 2002. 27(7): p. 
368-75. 
8. Pratt, W.B., et al., Chaperoning of glucocorticoid receptors. Handb Exp 
Pharmacol, 2006(172): p. 111-38. 
9. Meacham, G.C., et al., The Hsc70 co-chaperone CHIP targets immature CFTR 
for proteasomal degradation. Nat Cell Biol, 2001. 3(1): p. 100-5. 
10. Zhang, Y., et al., Parkin functions as an E2-dependent ubiquitin- protein ligase 
and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-
1. Proc Natl Acad Sci U S A, 2000. 97(24): p. 13354-9. 
11. Tsai, Y.C., et al., Parkin facilitates the elimination of expanded polyglutamine 
proteins and leads to preservation of proteasome function. J Biol Chem, 2003. 
278(24): p. 22044-55. 
12. Ballinger, C.A., et al., Identification of CHIP, a novel tetratricopeptide repeat-
containing protein that interacts with heat shock proteins and negatively 
regulates chaperone functions. Mol Cell Biol, 1999. 19(6): p. 4535-45. 
13. Morishima, Y., et al., CHIP deletion reveals functional redundancy of E3 ligases 
in promoting degradation of both signaling proteins and expanded glutamine 
proteins. Hum Mol Genet, 2008. 17(24): p. 3942-52. 
14. Jana, N.R., et al., Co-chaperone CHIP associates with expanded polyglutamine 
protein and promotes their degradation by proteasomes. J Biol Chem, 2005. 
280(12): p. 11635-40. 
15. Miller, V.M., et al., CHIP suppresses polyglutamine aggregation and toxicity in 
vitro and in vivo. J Neurosci, 2005. 25(40): p. 9152-61. 
16. Prodromou, C. and L.H. Pearl, Structure and functional relationships of Hsp90. 
Curr Cancer Drug Targets, 2003. 3(5): p. 301-23. 
17. Xu, Z., et al., Interactions between the quality control ubiquitin ligase CHIP and 
ubiquitin conjugating enzymes. BMC Struct Biol, 2008. 8: p. 26. 
18. Connell, P., et al., The co-chaperone CHIP regulates protein triage decisions 
mediated by heat-shock proteins. Nat Cell Biol, 2001. 3(1): p. 93-6. 
19. Brinker, A., et al., Ligand discrimination by TPR domains. Relevance and 
143 
selectivity of EEVD-recognition in Hsp70 x Hop x Hsp90 complexes. J Biol 
Chem, 2002. 277(22): p. 19265-75. 
20. Johnson, B.D., et al., Hop modulates Hsp70/Hsp90 interactions in protein folding. 
J Biol Chem, 1998. 273(6): p. 3679-86. 
21. Jiang, J., et al., CHIP is a U-box-dependent E3 ubiquitin ligase: identification of 
Hsc70 as a target for ubiquitylation. J Biol Chem, 2001. 276(46): p. 42938-44. 
22. Southworth, D.R. and D.A. Agard, Client-loading conformation of the Hsp90 
molecular chaperone revealed in the cryo-EM structure of the human Hsp90:Hop 
complex. Mol Cell, 2011. 42(6): p. 771-81. 
23. Stankiewicz, M., et al., CHIP participates in protein triage decisions by 
preferentially ubiquitinating Hsp70-bound substrates. Febs J, 2010. 277(16): p. 
3353-67. 
24. Qian, S.B., et al., CHIP-mediated stress recovery by sequential ubiquitination of 
substrates and Hsp70. Nature, 2006. 440(7083): p. 551-5. 
25. Scheufler, C., et al., Structure of TPR domain-peptide complexes: critical 
elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell, 
2000. 101(2): p. 199-210. 
26. Evans, C.G., et al., Improved synthesis of 15-deoxyspergualin analogs using the 
Ugi multi-component reaction. Bioorg Med Chem Lett, 2011. 21(9): p. 2587-90. 
27. Scaglione, K.M., et al., Ube2w and ataxin-3 coordinately regulate the ubiquitin 
ligase CHIP. Mol Cell, 2011. 43(4): p. 599-612. 
28. Brzovic, P.S. and R.E. Klevit, Ubiquitin transfer from the E2 perspective: why is 
UbcH5 so promiscuous? Cell Cycle, 2006. 5(24): p. 2867-73. 
29. Brzovic, P.S., et al., A UbcH5/ubiquitin noncovalent complex is required for 
processive BRCA1-directed ubiquitination. Mol Cell, 2006. 21(6): p. 873-80. 
30. Ruan, Q., J.P. Skinner, and S.Y. Tetin, Using nonfluorescent Forster resonance 
energy transfer acceptors in protein binding studies. Anal Biochem, 2009. 
393(2): p. 196-204. 
31. Murata, S., M. Minami, and Y. Minami, Purification and assay of the chaperone-
dependent ubiquitin ligase of the carboxyl terminus of Hsc70-interacting protein. 
Methods Enzymol, 2005. 398: p. 271-9. 
 
 
 
 
144 
 
 
 
 
Chapter 5 
Conclusions and Future Directions 
5.1 Conclusions 
The heat shock protein 70 (Hsp70) family of chaperones is central to proteostasis 
decisions in the cell. Importantly, Hsp70s do not function alone; rather, they are assisted 
by a variety of co-chaperones as part of distinct complexes. This thesis focused on 
understanding how these complexes are formed, the biochemical features that 
differentiate these complexes and the identification of chemical probes that selectively 
perturb these complexes. The ultimate goal of this work is to better understand the logic 
of protein quality control in the cell. 
When I first started working in the lab in 2006, there were only a few small molecules 
known to modulate the function of Hsp70s and these were often of dubious affinity and 
selectivity [1]. One of the reasons for this gap was that no HTS methods had been 
developed, severely limiting our capacity to identify potential inhibitors. Thus, from 
2007-2010, Lyra Chang, Sussane Wisen, Yoshi Miyata and I in the Gestwicki laboratory 
spearheaded efforts to develop the first high throughput screens for Hsp70s. Together, we 
developed the idea that the best way to find inhibitors of Hsp70 would be to target the 
critical co-chaperone regions. Thus, we developed the concept of ‘gray box’ screening (a 
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term first coined by Lyra Chang). One of my major contributions to this process was the 
first comprehensive analysis of the biochemical and biophysical properties of the DnaK 
and human Hsp70 complexes. We realized relatively early on that knowledge of the 
turnover rates and optimal ratios between Hsp70:co-chaperone would be critical to a 
good screen. Thus, I focused my efforts during the past five years at characterizing these 
systems to enable informed HTS efforts. Most recently, I worked with Tomoko 
Komiyama to carry out a screen of 100K compounds (described in Chapter 3). 
In addition, we found that it was important to deconvolute the target and mechanism of 
compounds after ‘gray box’ screening. While not as daunting as ‘black box’ screens, 
there are multiple potential targets in a screen against a reconstituted multi-protein 
complex, leading to greater urgency in understanding the mechanisms of the active 
compounds. My specific role in these efforts focused on the biophysical characterization 
of compounds, such as 115-7c, that were specific modulators of DnaK-DnaJ. In my 
opinion, the most fascinating finding was that I uncovered an unexpected allosteric 
mechanisms of action for 115-7c at the native protein-protein interface of DnaK and 
DnaJ. This interaction mimics the functional aspects of the natural co-chaperone DnaJ, 
despite the small size of the compound. This result could have far reaching implications 
in the study of inhibitors of protein-protein interactions. 
In Chapter 3 and 4, we extended our gray-box screening strategy to human Hsp70 
chaperone complexes. The first part of this process was originally intended to be a 
routine biochemical characterization of the turnover rates and affinity constants. 
However, both projects turned out to be much more interesting. Prior to these studies, the 
literature often assumed that, because of high sequence homology, the prokaryotic and 
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eukaryotic Hsp70 systems would behave similarly. Moreover, because the DnaK system 
had been best characterized, most experts in the field would assume that human Hsp70s 
would have similar properties. To be fair, we shared this notion. However, my studies 
strongly suggested that this assumption is false – the human Hsp70 system has many 
significant and important differences. For example, I found that not all J-proteins are 
functionally equivalent in our in vitro assays and that the NEFs are unable to stimulate 
the ATPase and refolding activities of human Hsp70s. We performed a HTS screen 
against one functionally competent chaperone complex Hsp72/DJA2/BAG2 and 
discovered a few promising lead hit compounds and efforts to characterize them are 
currently underway.  
When the chaperone machinery fails in attempts to fold substrate proteins, it actively 
targets them to various degradation pathways. Hsp70 in complex with the E3 ubiquitin 
ligase CHIP is central to promoting the ubiquitin dependent proteosomal degradation of 
proteins. We characterized the binding affinity for this complex and, for the first time, 
mapped the key domains that are involved in this interaction in vitro. We found that the 
TPR domain of CHIP is important, but not absolutely required, in the interaction with 
molecular chaperones and that it is essential for the substrate ubiquitylation function of 
CHIP. 
Together, my thesis projects are the first steps in understanding the molecular interactions 
involved in the assembly and functional outcomes of the Hsp70 chaperone complexes. 
The chemical probes identified will hopefully be useful in understanding the complicated 
biology of the Hsp70 family of proteins. 
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5.2 Future directions  
5.2.1 Utilizing small molecules to identify chaperone complexes that interact with 
disease relevant substrates 
As mentioned earlier, the combinatorial assembly of co-chaperones with Hsp70 leads to 
distinct outcomes, such as folding and degradation. To understand the role of Hsp70 as a 
triage machine, we need to understand the chaperone complexes that are associated with 
these outcomes. Further, we need to better understand which complexes are associated 
with specific disease-related substrates, such as tau [2-4]. One approach towards that end 
goal would be an unbiased proteomic approach in which we force the fate of a substrate 
using chemical probes and therefore enrich for a particular complex. For example, our 
“gray box” screens have identified Hsp70 inhibitors, such as 115-7c and methylene blue 
(MB), that dramatically and rapidly alter the fate of tau in HeLa cells, primary neurons 
and mouse brain slices [5, 6]. Andrea Thompson, a graduate student in the Gestwicki 
laboratory, is using mass spectrometry (MS) and co-immunoprecipitation of tau from 
HeLa cells to identify the chaperones that interact with tau after treatment with MB 
(Figure 5.1). Specifically, she treated cells with a combination of MB and a proteosomal 
inhibitor, bortezamib, to enrich for the complex of tau (with its associated chaperones) 
that is fated for degradation. The members of these complexes (e.g. the “play list”) might 
serve as good candidates for future ‘gray-box’ screening efforts. 
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5.2.2 Using chemical probes to dissect mechanistic details 
In our collaboration with the Dickey group, we have shown that Hsp70 is central to the 
processing of tau in cells and animals [5]. However, it isn’t yet clear how Hsp70 can 
distinguish between different tau variants, such as phosphorylated forms. As discussed in 
Chapter 1, J proteins are the co-chaperones that recruit Hsp70s into specific substrate 
interactions. Thus, one important future goal will be to identify the J protein that 
distinguishes “normal” from “abnormal” tau. Once J proteins that specifically stabilize 
abnormal tau are identified, we could develop inhibitors of this interaction in an attempt 
to destabilize tau. Although the work described in this thesis focused on the Hsp70-J 
protein interaction, future studies should also consider the J protein-substrate contact. 
 
5.2.3 Development of biophysical techniques to monitor ternary complex formation  
Techniques like SPR and ITC are very useful for determining the biophysical interactions 
between two binding partners. However, in the case of Hsp70, biology may be a product 
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of multiple co-chaperones and many protein-protein interactions. Thus, it will be useful 
to develop a technique to monitor the simultaneous assembly (and disassembly) of multi-
protein complexes.  
High Speed Capillary Electrophoresis (CE) with laser-induced fluorescence anisotropy 
(LIFA) detection is a promising solution to this problem. Briefly, one component (e.g.  
tau) could be labeled with a fluorophore and its interactions with partners, such as Hsp70, 
would result in the formation of a new peak (Figure 5.2). Likewise, additional partners 
(with unique labels) could 
be added to form larger 
and more heterogeneous 
complexes. This approach 
has been used to study 
interactions between SH2 
domains and its substrate 
peptides [7, 8]. These experiments would help us understand how the various co-
chaperones assemble into complexes.  
 
5.2.4 Potential multiplexed screens targeting the Hsp70 co-chaperone complexes  
In Chapter 3, we developed a flow cytometry-based binding platform where we could 
monitor the binding interaction between the BAG proteins and Hsp70. Because human 
BAG proteins do not seem to impact ATP turnover (see Chapter 3), this platform might 
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be used to find inhibitors. This is an important goal because the BAG proteins have other 
domains that determine, in part, the functional specificity of Hsp70 complexes.  
 
As envisioned, we would label the 
BAG proteins (BAG1-3) and CHIP 
with different fluorophores and 
perform the HTS screen against all 
the four components at the same time 
(Figure 5.3). We could then 
deconvolute the hit compounds after 
the primary screen, to determine their 
potential binding partner. This 
system may allow for the identification of chemical scaffolds targeting multiple Hsp70 
interactions in a single, multiplexed primary screen.  
5.3 Final Thoughts: 
We have now successfully discovered and developed the first generation of small 
molecule probes that can modulate the function and activity of Hsp70. The current suite 
of compounds display only modest affinity and are more suitable as chemical probes 
rather than therapeutics. Since, Hsp70 operates as part of a combinatorial multi-protein 
complex with multiple protein-protein interfaces and allosteric sites, the chemical tools 
that are currently available to us will prove very useful to probe the complex the biology 
of Hsp70. 
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